Immunosuppressant compounds and compositions

专利摘要:

公开号:AU2009200338A1
申请号:U2009200338
申请日:2009-01-30
公开日:2009-02-19
发明作者:Yi Fan；Wenqi Gao；Nathanael S. Gray；Tao Jiang；Yuan Mi；Shifeng Pan
申请人:IRM LLC；
IPC主号:C07D333-60

专利说明:
Australian Patents Act 1990 Regulation 3.2A ORIGINAL COMPLETE SPECIFICATION STANDARD PATENT Invention Title "Immunosuppressant compounds and compositions" The following statement is a full description of this invention, including the best method of performing it known to us:- Q OPERMJC726042 ne. di 030 doc IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS 0 CROSS-REFERENCE TO RELATED APPLICATIONS c 5 This application claims the benefit of priority to U.S. Provisional Patent Application SNumber 60/471,931 (filed 19 May 2003) and U.S. Provisional Patent Application Number C- 60/562,183 (filed 14 April 2004). The full disclosures of these applications are incorporated Sherein by reference in their entirety and for all purposes.
BACKGROUND OF THE INVENTION Field of the Invention The invention provides a novel class of immunosuppressant compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
Background EDG receptors belong to a family of closely related, lipid activated G-protein coupled receptors. EDG-1, EDG-3, EDG-5, EDG-6, and EDG-8 (also respectively termed S1PI, SIP3, S1P2, S1P4, and S1P5) are identified as receptors specific for sphingosine-1phosphate (SIP). EDG2, EDG4, and EDG7 (also termed LPA1, LPA2, and LPA3, respectively) are receptors specific for lysophosphatidic (LPA). Among the SIP receptor isotypes, EDG-1, EDG-3 and EDG-5 are widely expressed in various tissues, whereas the expression of EDG-6 is confined largely to lymphoid tissues and platelets, and that of EDG- 8 to the central nervous system. EDG receptors are responsible for signal transduction and are thought to play an important role in cell processes involving cell development, proliferation, maintenance, migration, differentiation, plasticity and apoptosis. Certain EDG receptors are associated with diseases mediated by lymphocyte interactions, for example, in transplantation rejection, autoimmune diseases, inflammatory diseases, infectious diseases and cancer. An alteration in EDG receptor activity contributes to the pathology and/or symptomology of these diseases. Accordingly, molecules that themselves alter the activity of EDG receptors are useful as therapeutic agents in the treatment of such diseases.
C) SUMMARY OF THE INVENTION This invention relates to compounds of Formula I: 00
R
6
R
5
R
3
R
2
R
8
R
7 CI in which: n islIor 2; A is chosen from -C(O)OR9, OP(O)(0R 9 2 P(O)(OR9) 2
-S(O)
2 0R 9
P(O)(R
9 )0R 9 and lH-tetrazol-5-yl; and R 9 is chosen from hydrogen and CI-6alcyl; X is a bond or is chosen from C 14 alkylene, -X 1 0X 2
-XINRI
0
X
2
XIC(O)NRIOX
2
-XINRIOC(O)X
2
-XIS(O)X
2
-XIS(O)
2
X
2
-X
1 SX2- and C 2 gheteroarylene; wherein X, and X 2 are independently chosen from a bond and C 1 3 alkylene; Rio is chosen from hydrogen and C 1 6 alkyl; and any heteroarylene of X is optionally substituted by a member of the group chosen from halo and CI.
6 allcyl; Y is a fused 5,6 or 6,6 hetero bicyclic ring system consisting of at least one aromatic ring, wherein said fused bicyclic ring system of Y can be optionally substituted with 1 to 3 radicals chosen from halo, hydroxy, cyano, nitro, CI-6alkyl, CI 1 6alkoxy, halosubstituted Ct-6alkyl and halo-substituted C 1 6 alkoxy; RI is chosen from C 6 ,oaryl and C 2 -gheteroaryl; wherein any aryl or heteroaryl of RI is optionally substituted by a radical chosen from C6-loarylCO-4alkyl, C 2 -gheteroarylCo.
4 alkyl, C 3 -8cycloalkylCo4alkyl, C 3 .8heterocycloalkYlCo.4alkyl or CI-6alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R, can be optionally substituted by 1 to 3 radicals chosen from halo, CI.
6 alkyl, C 1 -6alkoxy, halo-substituted-C 1 -6alkyl and halosubstituted-Ci- 6 alkoxy; and any alkyl group of RI can optionally have a methylene replaced by an atom or group chosen from -NR 10 and wherein RIO is chosen from hydrogen or C 1 -6allcyl;
R
2
R
3
R
5 Rs, R 7 and R 8 are independently chosen from hydrogen, Ci-6alkyl, halo, O hydroxy, C 1 .alkoxy, halo-substituted Ci-6alkyl and halo-substituted Cil-alkoxy;
R
4 is chosen from hydrogen and Ci-alkyl; or R 7 and either R 2
R
4 or R 5 together c' with the atoms to which R 2
R
4
R
5 and R 7 are attached forms a 4 to 7 member ring; wherein Cm 5 said 4 to 7 member ring is saturated or partially unsaturated; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers 00 c thereof; and the pharmaceutically acceptable salts and solvates hydrates) of such Scompounds.
C. A second aspect of the invention is a pharmaceutical composition which contains a 0 10 compound of Formula I or an N-oxide derivative, individual isomer or mixture of isomers c 1 thereof, or a pharmaceutically acceptable salt thereof, in admixture with one or more suitable excipients.
A third aspect of the invention is a method for treating a disease in an animal in which alteration of EDG receptor mediated signal transduction can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula I or a N-oxide derivative, individual isomer or mixture of isomers thereof; or a pharmaceutically acceptable salt thereof.
A fourth aspect of the invention is the use of a compound of Formula I in the manufacture of a medicament for treating a disease in an animal in which alteration of EDG receptor mediated signal transduction contributes to the pathology and/or symptomology of the disease.
A fifth aspect of the invention is a process for preparing compounds of Formula I and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts thereof.
DESCRIPTION OF THE PREFERRED EMBODIMENTS The invention provides compounds that are useful in the treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. Also provided are methods for treating such diseases or disorders.
Definitions SIn this specification, unless otherwise defined: N "Alkyl" as a group and as a structural element of other groups, for example halo- Ssubstituted-alkyl, alkoxy, acyl, alkylthio, alkylsulfonyl and alkylsulfinyl, can be either straight-chained or branched. "Alkenyl" as a group and as a structural element of other groups contains one or more carbon-carbon double bonds, and can be either straight-chain, 0 or branched. Any double bonds can be in the cis- or trans- configuration. "Alkynyl" as a group and as structural element of other groups and compounds contains at least one C EC 0 triple bond and can also contain one or more C=C double bonds, and can, so far as possible, 0 10 be either straight-chain or branched. Any cycloalkyl group, alone or as a structural element Ci of other groups can contain from 3 to 8 carbon atoms, preferably from 3 to 6 carbon atoms.
"Alkylene" and "alkenylene" are divalent radicals derived from "alkyl" and "alkenyl" groups, respectively. In this application, any alkyl group ofR' can be optionally interrupted by a member of the group selected from -S(O) 2
-NR
20 and (wherein
R
20 is hydrogen or C 1 6 alkyl). These groups include -CH 2 -0-CH 2
-CH
2 -S(0) 2
-CH
2
(CH
2 2
-NR
20
-CH
2
-CH
2
-(CH
2 2 and the like.
"Aryl" means a monocyclic or fused bicyclic aromatic ring assembly containing six to ten ring carbon atoms. For example, C 6 1 2 aryl can be phenyl, biphenyl or naphthyl, preferably phenyl. A fused bicyclic ring can be partially saturated, for example, 1,2,3,4tetrahydro-naphthalene, and the like. "Arylene" means a divalent radical derived from an aryl group. For example, arylene as used in this application can be phenylene, biphenylene, naphthylene and the like.
"Halo" or "halogen" means F, Cl, Br or I, preferably F or Cl. Halo-substituted alkyl groups and compounds can be partially halogenated or perhalogenated, whereby in the case of multiple halogenation, the halogen substituents can be identical or different. A preferred perhalogenated alkyl group is for example trifluoromethyl or trifluoromethoxy.
"Heteroaryl" means aryl, as defined in this application, with the addition of at least one heteroatom moiety selected from N, O or S, and each ring is comprised of 5 to 6 ring atoms, unless otherwise stated. For example, C2heteroaryl includes oxadiazole, triazole, and the like. Cgheteroaryl includes quinoline, 1,2,3,4-tetrahydro-quinoline, and the like. C 2 9 heteroaryl as used in this application includes thienyl, pyridinyl, furanyl, isoxazolyl, benzoxazolyl or benzo[ 1,3]dioxolyl, preferably thienyl, furanyl or pyridinyl.
0 "Heteroarylene" means heteroaryl, as defined in this application, provided that the ring assembly comprises a divalent radical. A fused bicyclic heteroaryl ring system can be partially saturated, for example, 2,3-dihydro-1H-isoindole, 1,2,3,4-tetrahydro-quinoline, and n 5 the like.
As used in the present invention, an EDG-1 selective compound (agent or 00 m modulator) has a specificity that is selective for EDG-1 over EDG-3 and over one or more of 0 EDG-5, EDG-6, and EDG-8. As used herein, selectivity for one EDG receptor (a "selective Sreceptor") over another EDG receptor (a "non-selective receptor") means that the compound has a much higher potency in inducing activities mediated by the selective EDG receptor EDG-1) than that for the non-selective SIP-specific EDG receptor. If measured in a GTP-yS binding assay (as described in the Example below), an EDG-1 selective compound typically has an EC50 (effective concentration that causes 50% of the maximum response) for a selective receptor (EDG-1) that is at least 5, 10, 25, 50, 100, 500, or 1000 fold lower than its EC50 for a non-selective receptor one or more of EDG-3, EDG-5, EDG-6, and EDG-8).
Detailed Description of the Invention The invention provides compounds that are useful for treating or preventing diseases or disorders that are mediated by lymphocyte interactions. In one embodiment, for compounds of Formula I, Ri is phenyl, naphthyl, furanyl or thienyl optionally substituted by C 6 1 oarylCo- 4 alkyl, C 2 .9heteroarylC-4alkyl, C 3 .scycloalkylCo4alkyl, C 3 .sheterocycloalkylCoalkyl or Ci- 6 alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of Ri can be optionally substituted by one to five radicals chosen from halo, Ci-alkyl, Ci.6alkoxy, halosubstituted-CI.6alkyl and halo-substituted-Ci.6alkoxy; and any alkyl group of RI can optionally have a methylene replaced by an atom or group chosen from
S(O)
2 -NRio- and wherein Rio is hydrogen or Ci-6alkyl.
In another embodiment, Y is chosen from:
N
R
11
N
N
R11 Nr S N
N
S
S
S N~ 0 N N r
N
N S 0 and wherein R11 is hydrogen or C 1 .alkyl; and the left and right asterisks ofY indicate the point of attachment between either -C(R 2
)(R
3 and X of Formula I or between X and
C(R
2
)(R
3 of Formula I, respectively; and Y can be optionally substituted with 1 to 3 radicals chosen from halo, hydroxy, cyano, nitro, C 1 -alkyl, C 1 6 alkoxy, halo-substituted C 1 6 alkyl and halo-substituted C 1 s6alkoxy.
In a further embodiment, R 1 is chosen from:
R
1 2 1 3 a ML and L R12 R12 wherein the asterisk is the point of attachment of R, with X; m is chosen from 1 and 2; R 1 2 is hydrogen, C 6 oarylCO-4alkyl, C 2 9 heteroarylCo4alkyl, C 38 cycloalkylCo-alkyl,
C
3 .sheterocycloalkylCo4alkyl or C 1 6 alkyl; wherein any aryl, heteroaryl, cycloallcyl or heterocycloalkyl group of R 12 can be optionally substituted by one to three radicals chosen from halo, CI-6alkyl, C 1 s6alkoxy, halo-substituted-C -alkyl and halo-substituted-CI alkoxy; and any alkyl group of R 12 can optionally have a methylene replaced by an atom or group chosen from -S(0) 2 -NRIO- and wherein RIO is hydrogen or C 1 -6alkyl; and R 13 is chosen from halo, C,-6alkyl, CI-6alkoxy, halo-substituted-C 1 -6alcyl and halosubstituted-C 1 6alkoxy.
In another embodiment, A is C(0)OH; R2, R(3, R5, R 6 and RS are hydrogen; R 7 is chosen from hydrogen and fluoro; R 4 is chosen from hydrogen and C 1 -alkyI; or R(7 and R 4 together with the atoms to which R 7 and R4 are attached forms azetidine.
In a further embodiment, Y is chosen from:
N
R
11 N S
N
-NJJD
N /N~
S
00 an
NJ
0 wherein R, 1 is hydrogen or CI.
6 alkyl; and the left and right asterisks of Y indicate the point of attachment between either -C(R 2
)(R
3 and X of Formula I or between X and
C(R
2
)(R
3 of Formula 1, respectively; and Y can be optionally substituted with 1 to 3 radicals chosen from chioro, fluoro, methyl, ethyl, cyano and bromo.
In another embodiment, X is chosen from a bond, -Nil- and -N(CH 3 and R, is chosen from:
(R
1 3'% an R12).wherein m is chosen from 1 and 2; R12 is hydrogen, phenyl, piperidinyl, 2-methylbutyl, 3-methyl-butyl, cyclohexyl, cyclohexyl-oxy, cyclopentyl-oxy, sec-butoxy, tetrahydropyranyl, phenoxy, benzo[1I,3]dioxolyl, naphthyl, 2,27dimethyl-pentyl, butyl, benzo[blfuranyl, benzyl, phenethyl, phenyl-ethenyl, I1-phenyl-ethyl and cyclopropyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R 12 can be optionally substituted by one to three radicals chosen from fluoro, isobutyl, 2-methyl-butyl, tiifluoromethyl, chioro, methyl, trifluoromethoxy and methoxy; and R 13 is chosen from M 5 trifluoromethyl, trifluoromethoxy, methyl, fluoro, chioro and methoxy.
Preferred compounds of the invention are chosen from 3-{[2-(2-trifluoromethyl- 00 M biphenyl-4-yl)-benzo[b]thiophen-5-ylmethyl]-amino) -propionic acid, 3- {[2-(4-piperidin- 1y1-3-trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl]-amfino) -propionic acid, 3- CI(2-Tri fluoromethyl-biphenyl-4-yl)-thieno[2,3 -b]pyridin-5 -ymethyl -amino}I -propionic acid, 3 [2-(2-Tri fluoromethyl-biphenyl-4-y1)-benzo [b]thiophen-6-ylmethyl] -amino) -propionic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4-yl)-2,3-dihydro- IH-isoindol-5-ylmethyl l-amino) propionic acid, 3- {[2-(2-TrifluoromethyF .biphenyl-4-yl)-benzooxazol-5-ylmethyl]-amino) propionic acid, I -[2-(4-Isobutyl-3-trifluoromethyl-phenyl)-benzooxazol-6-ylmethyl]azetidine-3-carboxylic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4-yl)-benzofuran-5ylmethyl] -amnino) -propionic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4-yl)-benzothiazol-6ylmethyl] -amino) -propionic acid, 3- -Chloro-2-(2-tri fluoromethyl-biphenyl-4-yI)- -propionic acid, 1 -[2-(2-Trifluoromethyl-biphenyl-4yl).benzo[b]thiophen-5-ylnethylj-azetidine-3-carboxylic acid, 3- [[2-(2'-Fluoro-2- }-propionic acid, 3- (5-Fluoro-2-trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophen-6-ylmethyl] -amino) -propionic acid, 3- {[3-Fluoro-2-(2-trifluoromethy1-bipheny1-4-yl)-benzoI~b]thiophen-5-yllethyl]amino) -propionic acid, 3- {[2-(4-Cyclohexyl-3-trifluoromethyl-phenyl)-benzo[b]thiophen-5ylmethyl]-amino} -propionic acid, 3- {[4-Chloro-2-(2-trifluoromethyl-biphenyl-4-yI)benzo[b] thiophen-5 -ylnethyl] -amino) -propionic acid, 1 -[2-(4-Cyclohexyl-3trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylfethyl]-azetidile-3 -carboxylic acid, 3- Methoxy-2-(2-tri fluoromethyl-biphenyl-4-yl)-belzo [b]thiophel-5 -ylmethyl -amino)} propionic acid, 3- {[6-Chloro-2-(2-trifluoromethyl-biphenyl-4-yl)-benzo~b]thiophen-5ylmethyl] -amino) -propionic acid, 3- {[2-(4-Cyclopentyloxy-3-trifluoromethyl-phenyl)benzo[b] thiophen-5-yhncthyl]-amino} -propionic acid, 3- {[2-(4-sec-Butoxy-3trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylifethyl]-amino) -propionic acid, 3- {[2-(4-secacid, 3- C ~[2-(4-Isobutyl-3 -trifluoromethyl-phenyl)-benzo[b] thiophen-5 -ylmethyl] -amino}I -propionic 0 acid, 3- {[2-(4-Cyclohexyloxy-3
(N
amino) -propionic acid, 3 {2-[4-(Tetrahydro-pyran-4-yl)-3-trifluoromethyl-phenyl]- -amino)-propionic acid, 3- -Methyl-2-(2-trifluoromethyl- CM 5 biphenyl-4-yl)-benzo[b]thiophen-5-ylmethyl]-amino} -propionic acid, 3- {[3-Cyano-2-(2trifluoromethyl-biphenyl-4-yl)-benzo thiophen-5 -ylniethyl] -amino) -propiomc acid, 3- 00 Broino-2-(2-trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophen-5-ylmethyl] -amino) -propionic acid, -Fluoro-5 -tri fluoromethyl-phenyl)-benzo[b] thiophen-5 -ylmethyl] -amino) (Ni propionic acid, 3- {[2-(2-Fluoro-3-trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl]amino) -propionic acid, 3- {[2-(2-Trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl]amino) -propionic acid, 1 -[2-(2-Trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophen-4ylmethyl]-azetidine-3-carboxylic acid, 3- {[2-(4-Chloro-3-trifluoromethyl-phenyl)- -ylmethyl] -amino) -propionic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4yl)-benzo thiophen-4-ylmethyl] -amino) -propionic acid, 3- {[2-(2,5-Bis-tri fluoromethylphenyl)-benzo[b]thiophen-5-ylmetnyl]-amnino) -propionic acid, 3- {[2-(2-Methyl-5 -amino) -propionic acid, 3-[(2-Phenylbenzo thiophen-5 -ylmethyl)- amino] -propionic acid, 3- {[2-(4-Methyl-3-trifluoromethyl- -amnino) -propionic acid, I -[2-(3-Trifluoromethylphenyl)-benzo[b] thiophen-5-ylmethyl]-azetidine-3-carboxylic acid, 3- {[2-(4-Fluoro-3trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl]-amino) -propionic acid, 2-Fluoro-3- [2-(3-trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl]-amino)}-propionic acid, 3- (3,5-Bis-trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl]-amino) -propionic acid, 3f{[2-(4-Trifluoromethoxy-phenyl)-benzo[b]thiophen-5-ylmethyl]-amino) -propionic acid, 1 [2-(2-Fluoro-5-trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl)-azetidine-3 carboxylic acid, 3- ([2-(2-Chloro-5 -trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl] amino) -prop ionic acid, 3- {[2-(3-Trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl]amino) -propionic acid, I -[2-(3-Trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl]pyrrolidine-3-carboxylic acid, 3- {[2-(2-Fluoro-5-trifluoromethyl-phenyl)-benzo[b]thiophenacid, 3- {[2-(4-Tri ylmethyl]-amnino) -propionic acid, 3- {[2-(4-Methoxy-3-trifluoromethyl-phenyl)benzollb] thiophen-5-ylmethyl] -amino) -propionic acid, 3- {[2-(2-Methoxy-5-trifluoromethyl- -propionic acid, 3- {[3-(2-Trifluoromethyl- -propionic acid, 3- Trifluoromethyl-biphenyl-4-yl)-benzo[blthiophen-2-ylmnethyl] -amino) -propionic acid, 3- [5 -(4-Cyclohexyl-3 -trifluoromethyl-phenyl)-benzo[b]thiophen-2-ylnethyl] -amino) M~ 5 propionic acid, 3- {[3-Chloro-5-(2-trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophen-2ylmethyl] -amino) -propionic acid, 1 -[5-(2-Trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophen- 00 M 2-ylmethyl]-azetidine-3-carboxylic acid, 3- ([3-Bromo-5-(2-trifluoromethyl-biphenyl-4-yl)benzo~b]thiophen-2-ylmethyl] -amino) -propionic acid, 3- {[2-(2'-Fluoro-2-trifluoromethyl- (Ni biphenyl-4-yl)-benzooxazol-5-yhnethyl]-amino) -propionic acid, 3- {[2-(3'-Fluoro-2trifluoromethyl-biphenyl-4-yl)-benzooxazol-5-ylmethyl]-amino)}-propionic acid, 3- Chloro-2-trifluoromethyl-biphcnyl-4-yl)-benzooxazol-5-ylmethyl] -amino) -propionic acid, 3- ({[2-(4-Phenoxy-3 -trifluoromethyl-phenyl)-benzooxazol-5-ylmethyl] -amino) -propionic acid, 3- [2-(2'-Fluoro-2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl] -amino) propionic acid, 3- {[2-(4-Cyclohexyl-3-trifluoromethyl-phenyl)-benzooxazol-6-ymethyl]amino) -propionic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl] amino) -propionic acid, 3- {[2-(5'-Fluoro-2'-methyl-2-trifluoromethyl-biphenyl-4-yl)benzooxazol-6-ylmethyl] -amino) -propionic acid, 2-Fluoro-3- {[2-(2'-fluoro-2trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl] -amino) -prop ionic acid, 3- Dichloro-2-(2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl]-amino} -propionic acid, 3- {[2-(3'-Chloro-2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethy] -amino) propionic acid, 3- {[5-Chloro-2-(2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylniethyl]amino) -propionic acid, 3- {[5-Bromo-2-(2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-6ylmethyl] -amino) -propionic acid, 3- {[2-(4-Isobutyl-3-trifluoromethyl-phenyl)-benzooxazol- 6-ylmethyl]-amino} -propionic acid, 3- {[2-(4-Benzo[ 1,3]dioxol1-5-yl-3-trifluoromethylphenyl)-benzooxazol-6-ylmethyll-amino) -propionic acid, 3- {[2-(4-Cyclohexyl-3-fluorophenyl) -benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- {[2-(2-Fluoro-biphenyl-4-yl)benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- {[2-(3'-Chloro-4'-fluoro-2trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl]-amino} -propionic acid, 3- sec-Butyl-3-trifluoromethyl-phenyl)-benzooxazol-6-ylmethyl]-amino)}-propionic acid, 3- Ethyl-2-(2-trifluoromcthyl-biphenylA-yl)-benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- {[2-(4-Naphthalen-2-yl-3-trifluoromethyl-phenyl)-benzooxazol-6-ylniethyl]-amino} C propiomic acid, 1- {2.[4-(2,2-Dimethyl-propyl)-3-trifluoromethyl-phenyl]-benzooxazol-6ylmethyl)}-azetidine-3-carboxylic acid, 3- {[2-(4-Butyl-3-trifluoromethyl-phenyl)benzooxazol-6-ylmethyl] -amino) -propiolic acid, 3- {[2-(4-Benzofuran-2-yl-3tri fluoromethyl-phenyl)-benzooxazol-6-ylmethyl] -aminlo) -propionic acid, M 5 Difluoro-benzyl)-3-trifluoromethyl-phenyl]-bezooxazol-6-ylmethyl}-amio)-propioflic acid, 3- {[2-(4-Phenethyl-3 -trifluoromethyl-phenyl)-benzooxazol-6-ylmethyl]-amino} 00 Mpropiomic acid, 3- {[2-(4-Styryl-3 -trifluoroniethyl-phenyl)-benzooxazol-6-ylmethyl]-amino} propionic acid, I-Phenyl-ethyl)-3 -trifluoromcthyl-phenyl]-benzooxazol-6- (N ylmethyl) -amino)-propionic acid, 3- '-Fluoro-2'-methoxy-2-trifluoromethyl-biphenyl- 4-yI)-benzooxazol-6-ylmethyl]-methyl-amilo}-propionic acid, 3- {[2-(5'-Fluoro-2'-methoxy- 2-tiifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl]-ailo}-propionic acid, 3- Trifluoromethyl-phenyl)-benzooxazol-6-ylmethyl]-ino} -propionic acid, 3- {[2-(4-tert- Butyl-phenyl)-benzooxazol-6-ylmethyl]-amilol-propionic acid, 1 -[2-(2-Fluoro-5trifluoromethyl-phenyl)-benzooxazol-6-ylmethyl]-azetidine-3-carboxylic acid, 3- 2-(3-trifluoromethyl-phenyl)-benzooxazol-6-ylmethyl] -amiino) -propionic acid, I Fluoro-5-trifluoromethyl-phenyl)-benzooxazol-5-ylethy]-azetidile-3-carboxylic acid, 1- [2-(2-Fluoro-5-trifluoromethy-pheny)-benzofural-5-yflmethy]-azetidile-3-carboxyic acid, 3- {[2-(4-Chloro-3-trifluoromethyl-phenyl)-benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- ({[2-(4-Cyclopropyl-3 -trifluoromethyl-phenyl)-benzooxazol-6-yhlethyl] -amino) -propionic acid, 3 {[2-(4-Fluoro-phenyl)-benzooxazol-6-ylmethyl] -anfo)} -propionic acid, 3- Fluoro-phenyl)-benzooxazol-6-ylmthyl]-amilo} -propionic acid, 3- {[2-(2-Fluoro-phenyl)benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- {[2-(4-Cyclohexyl-3-trifluoromethyl- -ylmethyl] -amino) -propionic acid, 3- 2-(4-Cyclohexyl-3trifluoromethyl-phenyl)-2,3-dihydro- I H-isoindol-5-ylmethyl] -amino) -propionic acid, 3-1[f2- (4-Cyclohexyl-3 -trifluoromethyl-phelyl)-2H-isoifdldO5-ylmethyl] -amlino) -propionic acid, 3- {[2-(2-Trifluorornethyl-biphenyl-4-yl)-benizothiazol-5 -ylmethyl]-amnino) -propionic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4-yl)-benzothiazol-7-ylmethyl]-amino} -propionic acid, 3 {[2-(3-Tri fluoromethyl-phenyl)-benzothiazol-7-ylmethyl] -amino)} -propionic acid, 3- (2-Trifluoromthy-biphenyl-4-yl)-2H-indazo-6-ylmethyl] -amino)} -propionic acid, 3- Fluoro-2-trifluoromethyl-biphenyl-4-yI)-2H-indazol-6-ylmethyl] -amino) -propionic acid, 1- [2-(5-Fluoro-2-trifluoromthyl-biphenyl-4-y)-2H-indazol-6-yhnlethyl]-azetidifle-3carboxylic acid, 1-[2-(2-Trifluoromethyl-biphenyl-4-yl)-IH-benzoimidazol-5-ylmethyl]- Sazetidine-3-carboxylic acid, 3-{[3-Methyl-2-(2-trifluoromethyl-biphenyl-4-yl)-3Hacid, -Methyl-2-(2-trifluoromethylc biphenyl-4-yl)- 1H-benzoimidazol-5-ylmethyl]-amino}-propionic acid, m 5 Trifluoromethyl-biphenyl-4-ylmethyl)-2,3-dihydro-H-isoindol-5-ylmethyl]-amino} propionic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4-ylamino)-benzooxazol-5-ylmethyl]- 00 Samino} -propionic acid, {2-[Methyl-(2-trifluoromethyl-biphenyl-4-yl)-amino]acid, 3-{[4-Oxo-2-(2-trifluoromethyl-biphenyl- N 4-yl)-4H-chromen-7-ylmethyl]-amino}-propionic acid, 3-{[4-Oxo-2-(2-trifluoromethylbiphenyl-4-yl)-4H-chromen-6-ylmethyl]-amino}-propionic acid and 1-[4-Oxo-2-(2c trifluoromethyl-biphenyl-4-yl)-4H-chromen-6-ylmethyl]-azetidine-3-carboxylic acid.
Further preferred compounds are also shown in the examples and table 1, infra.
The invention provides forms of the compound that have the hydroxyl or amine group present in a protected form; these function as prodrugs. Prodrugs are compounds that are converted into an active drug form after administration, through one or more chemical or biochemical transformations. Forms of the compounds of the present invention that are readily converted into the claimed compound under physiological conditions are prodrugs of the claimed compounds and are within the scope of the present invention. Examples of prodrugs include forms where a hydroxyl group is acylated to form a relatively labile ester such as an acetate ester, and forms where an amine group is acylated with the carboxylate group of glycine or an L-amino acid such as serine, forming an amide bond that is particularly susceptible to hydrolysis by common metabolic enzymes.
Compounds of Formula I can exist in free form or in salt form, e.g. addition salts with inorganic or organic acids. Where hydroxyl groups are present, these groups can also be present in salt form, e.g. an ammonium salt or salts with metals such as lithium, sodium, potassium, calcium, zinc or magnesium, or a mixture thereof. Compounds of Formula I and their salts in hydrate or solvate form are also part of the invention.
When the compounds of Formula I have asymmetric centers in the molecule, various optical isomers are obtained. The present invention also encompasses enantiomers, racemates, diastereoisomers and mixtures thereof. Moreover, when the compounds of Formula I include geometric isomers, the present invention embraces cis-compounds, transcompounds and mixtures thereof. Similar considerations apply in relation to starting 0 Smaterials exhibiting asymmetric carbon atoms or unsaturated bonds as mentioned above.
Methods and Pharmaceutical Compositionsfor Treating Immunomodulatory Conditions rn 5 The compounds of Formula I in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, e.g. lymphocyte recirculation modulating 00oO Sproperties, for example, as indicated by the in vitro and in vivo tests of Example 6 and are Stherefore indicated for therapy. Compounds of Formula I preferably show an EC5o in the C1 range of 1x 0I x 10 x 10' M, preferably less than 50nM. The compounds exhibit 0 10 selectivity for one or more EDG/S1P receptors, preferably EDG-1/S1P-1. EDG-1/SlP-1 C selective modulators of the present invention can be identified by assaying a compound's binding to EDG-1/S1P-1 and one or more of the other EDG/S1P receptors EDG- 3/S1P-3, EDG-5/S1P-2, EDG-6/S1P-4, and EDG-8/S An EDG- /SIP-1 selective modulator usually has an EC50 for the EDG-1/S1P-l receptor in the range of 1 x 100"1 to 1 x 10- 5 M, preferably less than 50 nM, more preferably less than 5 nM. It also has an for one or more of the other EDG/S1P receptors that is at least 5, 10, 25, 50, 100, 500, or 1000 fold higher than its EC50 for EDG-1/S1P-1. Thus, some of the EDG-1/S1P-1 modulatory compounds will have an EC50 for EDG-1/S1P-1 that is less than 5 nM while their EC50 for one or more of the other EDG/S1P receptors are at least 100 nM or higher.
Other than assaying binding activity to the EDG/S1P receptors, EDG-1/S1P-1 selective agents can also be identified by examining a test agent's ability to modify a cellular process or activity mediated by an EDG/S1P receptor.
The compounds of formula I are, therefore, useful in the treatment and/or prevention of diseases or disorders mediated by lymphocytes interactions, for example in transplantation, such as acute or chronic rejection of cell, tissue or organ allo- or xenografts or delayed graft function, graft versus host disease, autoimmune diseases, e.g. rheumatoid arthritis, systemic lupus erythematosus, hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, psoriasis, Graves ophthalmopathy, alopecia areata and others, allergic diseases, e.g. allergic asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, allergic contact dermatitis, inflammatory diseases optionally with underlying aberrant reactions, e.g. inflammatory bowel disease, Crohn's disease or ulcerative Scolitis, intrinsic asthma, inflammatory lung injury, inflammatory liver injury, inflammatory 0 glomerular injury, atherosclerosis, osteoarthritis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, cutaneous manifestations of m 5 immunologically-mediated disorders, inflammatory eye disease, keratoconjunctivitis, myocarditis or hepatitis, ischemia/reperfusion injury, e.g. myocardial infarction, stroke, gut 00 c ischemia, renal failure or hemorrhage shock, traumatic shock, T cell lymphomas or T cell 0 leukemias, infectious diseases, e.g. toxic shock superantigen induced), septic shock, (1 adult respiratory distress syndrome or viral infections, e.g. AIDS, viral hepatitis, chronic O 10 bacterial infection, or senile dementia. Examples of cell, tissue or solid organ transplants c include e.g. pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus. For the above uses the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired.
Furthermore, the compounds of formula I are useful in cancer chemotherapy, particularly for cancer chemotherapy of solid tumors, e.g. breast cancer, or as an antiangiogenic agent.
The required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5 mg/kg per body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 100 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form. Suitable unit dosage forms for oral administration comprise from ca. 1 to 50 mg active ingredient.
The compounds of Formula I can be administered by any conventional route, in particular enterally, for example, orally, e.g. in the form of tablets or capsules, or parenterally, for example, in the form of injectable solutions or suspensions, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form.
Pharmaceutical compositions comprising a compound of Formula I in free form or in pharmaceutically acceptable salt form in association with at least one pharmaceutical acceptable carrier or diluent can be manufactured in conventional manner by mixing with a 0 pharmaceutically acceptable carrier or diluent.
SThe compounds of Formula I can be administered in free form or in pharmaceutically acceptable salt form, for example, as indicated above. Such salts can be S 5 prepared in a conventional manner and exhibit the same order of activity as the free compounds.
00oO MIn accordance with the foregoing the present invention further provides: 1.1 A method for preventing or treating disorders or diseases mediated by C lymphocytes, e.g. such as indicated above, in a subject in need of such treatment, which 0 10 method comprises administering to said subject an effective amount of a compound of Sformula I or a pharmaceutically acceptable salt thereof; 1.2 A method for preventing or treating acute or chronic transplant rejection or Tcell mediated inflammatory or autoimmune diseases, e.g. as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof; 1.3 A method for inhibiting or controlling deregulated angiogenesis, e.g.
sphingosine-1-phosphate (S 1 P) mediated angiogenesis, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
1.4 A method for preventing or treating diseases mediated by a neo-angiogenesis process or associated with deregulated angiogenesis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
2. A compound of formula I, in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical, e.g. in any of the methods as indicated under 1.1 to 1.4 above.
3. A pharmaceutical composition, e.g. for use in any of the methods as in 1.1 to 1.4 above comprising a compound of formula I in free form or pharmaceutically acceptable salt form in association with a pharmaceutically acceptable diluent or carrier therefor.
4. A compound of formula I or a pharmaceutically acceptable salt thereof for use
O
O in the preparation of a pharmaceutical composition for use in any of the method as in 1.1 to S1.4 above.
ct c' The compounds of formula I may be administered as the sole active ingredient or M 5 in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or oO c prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune 0 disorders, or a chemotherapeutic agent, e.g. a malignant cell anti-proliferative agent. For C1 example the compounds of formula I may be used in combination with a calcineurin 0 10 inhibitor, e.g. cyclosporin A or FK 506; a mTOR inhibitor, e.g. rapamycin, 40-0-(2c N hydroxyethyl)-rapamycin, CCI779, ABT578 or AP23573; an ascomycin having immunosuppressive properties, e.g. ABT-281, ASM981, etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic acid; mycophenolate mofetil; 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; immunosuppressive monoclonal antibodies, e.g. monoclonal antibodies to leukocyte receptors, e.g. MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD45, CD58, CD80, CD86 or their ligands; other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y adhesion molecule inhibitors, e.g. LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or a chemotherapeutic agent.
By the term "chemotherapeutic agent" is meant any chemotherapeutic agent and it includes but is not limited to, i. an aromatase inhibitor, ii. an anti-estrogen, an anti-androgen (especially in the case of prostate cancer) or a gonadorelin agonist, iii. a topoisomerase I inhibitor or a topoisomerase II inhibitor, iv. a microtubule active agent, an alkylating agent, an antineoplastic antimetabolite or a platin compound, v. a compound targeting/decreasing a protein or lipid kinase activity or a protein or Slipid phosphatase activity, a further anti-angiogenic compound or a compound which induces cell differentiation processes, vi. a bradykinin 1 receptor or an angiotensin II antagonist, C 5 vii. a cyclooxygenase inhibitor, a bisphosphonate, a histone deacetylase inhibitor, a heparanase inhibitor (prevents heparan sulphate degradation), e.g. PI-88, a biological 00 response modifier, preferably a lymphokine or interferons, e.g. interferon 0, an 0 ubiquitination inhibitor, or an inhibitor which blocks anti-apoptotic pathways, C viii. an inhibitor of Ras oncogenic isoforms, e.g. H-Ras, K-Ras or N-Ras, or a farnesyl transferase inhibitor, e.g. L-744,832 or DK8G557,
C
ix. a telomerase inhibitor, e.g. telomestatin, x. a protease inhibitor, a matrix metalloproteinase inhibitor, a methionine aminopeptidase inhibitor, e.g. bengamide or a derivative thereof, or a proteosome inhibitor, e.g. PS-341, and/or xi. a mTOR inhibitor.
The term "aromatase inhibitor" as used herein relates to a compound which inhibits the estrogen production, i.e. the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole. A combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, e.g. breast tumors.
The term "anti-estrogen" as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. A combination of the invention comprising a chemotherapeutic agent which is an anti-estrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g. breast tumors.
The term "anti-androgen" as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide.
The term "gonadorelin agonist" as used herein includes, but is not limited to Sabarelix, goserelin and goserelin acetate.
The term "topoisomerase I inhibitor" as used herein includes, but is not limited to topotecan, irinotecan, 9-nitrocamptothecin and the macromolecular camptothecin conjugate c 5 PNU-166148 (compound Al in W099/17804).
The term "topoisomerase II inhibitor" as used herein includes, but is not limited to 00 C the anthracyclines such as doxorubicin, daunorubicin, epirubicin, idarubicin and Snemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines c etoposide and teniposide.
The term "microtubule active agent" relates to microtubule stabilizing and microtubule destabilizing agents including, but not limited to taxanes, e.g. paclitaxel and docetaxel, vinca alkaloids, vinblastine, especially vinblastine sulfate, vincristine especially vincristine sulfate, and vinorelbine, discodermolides and epothilones and derivatives thereof, e.g. epothilone B or a derivative thereof.
The term "alkylating agent" as used herein includes, but is not limited to busulfan, chlorambucil, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or GliadelT).
The term "antineoplastic antimetabolite" includes, but is not limited to fluorouracil, capecitabine, gemcitabine, cytarabine, fludarabine, thioguanine, methotrexate and edatrexate.
The term "platin compound" as used herein includes, but is not limited to carboplatin, cis-platin and oxaliplatin.
The term "compounds targeting/decreasing a protein or lipid kinase activity or further anti-angiogenic compounds" as used herein includes, but is not limited to protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g.
compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFR, ErbB2, ErbB3, ErbB4 as homo- or heterodimers), the vascular endothelial growth factor family of receptor tyrosine kinases (VEGFR), the platelet-derived growth factor-receptors (PDGFR), the fibroblast growth factor-receptors (FGFR), the insulin-like growth factor receptor 1 (IGF-IR), the Trk receptor tyrosine kinase family, the Axl receptor tyrosine kinase family, the Ret receptor tyrosine kinase, the Kit/SCFR receptor tyrosine kinase, members of the c-Abl family and their gene- Sfusion products BCR-Abl), members of the protein kinase C (PKC) and Raf family of Sserine/threonine kinases, members of the MEK, SRC, JAK, FAK, PDK or PI(3) kinase family, or of the PI(3)-kinase-related kinase family, and/or members of the cyclin-dependent C 5 kinase family (CDK) and anti-angiogenic compounds having another mechanism for their activity, e.g. unrelated to protein or lipid kinase inhibition.
00 C Compounds which target, decrease or inhibit the activity of VEGFR are especially Scompounds, proteins or antibodies which inhibit the VEGF receptor tyrosine kinase, inhibit a CI VEGF receptor or bind to VEGF, and are in particular those compounds, proteins or 10 monoclonal antibodies generically and specifically disclosed in WO 98/35958, e.g. 1-(4chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, e.g. the succinate, in WO 00/27820, e.g. a N-aryl(thio) anthranilic acid amide derivative e.g.
2-[(4-pyridyl)methyl]amino-N-[3-methoxy-5-(trifluoromethyl)phenyl]benzamide or oxido-4-pyridyl)methyl]amino-N-[3-trifluoromethylphenyl]benzamide, or in WO 00/09495, WO 00/59509, WO 98/11223, WO 00/27819 and EP 0 769 947; those as described by M.
Prewett et al in Cancer Research 59 (1999) 5209-5218, by F. Yuan et al in Proc. Natl. Acad.
Sci. USA, vol. 93, pp. 14765-14770, Dec. 1996, by Z. Zhu et al in Cancer Res. 58, 1998, 3209-3214, and by J. Mordenti et al in Toxicologic Pathology, Vol. 27, no. 1, pp 14-21, 1999; in WO 00/37502 and WO 94/10202; Angiostatin
T
described by M. S. O'Reilly et al, Cell 79, 1994, 315-328; Endostatin
T
described by M. S. O'Reilly et al, Cell 88, 1997, 277- 285; anthranilic acid amides; ZD4190; ZD6474; SU5416; SU6668; or anti-VEGF antibodies or anti-VEGF receptor antibodies,e.g. RhuMab.
By antibody is meant intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibody fragments so long as they exhibit the desired biological activity.
Compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, e.g. EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, or which have a dual inhibiting effect on the ErbB and VEGF receptor kinase and are in particular those compounds, proteins or monoclonal antibodies generically and specifically disclosed in WO 97/02266, e.g. the compound of ex. 39, or in EP 0 564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 S787 722, EP 0 837 063, US 5,747,498, WO 98/10767, WO 97/30034, WO 97/49688, WO 97/38983 and, especially, WO 96/30347 compound known as CP 358774), WO 96/33980 compound ZD 1839) and WO 95/03283 compound ZM105180) or c 5 PCT/EP02/08780; e.g. trastuzumab (HerpetinR), cetuximab, Iressa, OSI-774, CI-1033, EKB- 569, GW-2016, El.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3.
00 0 Compounds which target, decrease or inhibit the activity of PDGFR are especially O compounds which inhibit the PDGF receptor, e.g. a N-phenyl-2-pyrimidine-amine derivative, e.g. imatinib.
Compounds which target, decrease or inhibit the activity of c-AbI family members and their gene fusion products are, e.g. a N-phenyl-2-pyrimidine-amine derivative, e.g.
imatinib; PD180970; AG957; or NSC 680410.
Compounds which target, decrease or inhibit the activity of protein kinase C, Raf, MEK, SRC, JAK, FAK and PDK family members, or PI(3) kinase or PI(3) kinase-related family members, and/or members of the cyclin-dependent kinase family (CDK) are especially those staurosporine derivatives disclosed in EP 0 296 110, e.g. midostaurin; examples of further compounds include e.g. UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; Ilmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521; or LY333531/LY379196.
Further anti-angiogenic compounds are e.g. thalidomide (THALOMID) and TNP- 470.
Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are, e.g. inhibitors of phosphatase 1, phosphatase 2A, PTEN or CDC25, e.g.
okadaic acid or a derivative thereof.
Compounds which induce cell differentiation processes are, e.g. retinoic acid, a-, y- or 8-tocopherol or y- or 6-tocotrienol.
The term cyclooxygenase inhibitor as used herein includes, but is not limited to, e.g. celecoxib (CelebrexR), rofecoxib (VioxxR), etoricoxib, valdecoxib or a 5-alkyl-2arylaminophenylacetic acid, e.g. 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid.
The term "histone deacetylase inhibitor" as used herein includes, but is not limited to MS-27-275, SAHA, pyroxamide, FR-901228 or valproic acid.
The term "bisphosphonates" as used herein includes, but is not limited to, etridonic, Sclodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid.
The term "matrix metalloproteinase inhibitor" as used herein includes, but is not limited to collagen peptidomimetic and non-petidomimetic inhibitors, tetracycline c 5 derivatives, e.g. hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat, prinomastat, BMS-279251, BAY 12-9566, TAA211 or AAJ996.
00 C The term "mTOR inhibitor" as used herein includes, but is not limited to O rapamycin (sirolimus) or a derivative thereof, e.g. 32-deoxorapamycin, 16-pent-2-ynyloxy-
C
32-deoxorapamycin, 16-pent-2-ynyloxy-32(S)-dihydro-rapamycin, 16-pent-2-ynyloxy- 32(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin and, more preferably, 40-0-(2-hydroxy-
C
ethyl)-rapamycin. Further examples of rapamycin derivatives include e.g. CCI779 or 40- [3hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin or a pharmaceutically acceptable salt thereof, as disclosed in USP 5,362,718, ABT578 or rapamycin, particularly 40-epi-(tetrazolyl)-rapamycin, e.g. as disclosed in WO 99/15530, or rapalogs as disclosed e.g. in WO 98/02441 and WO01/14387, e.g. AP23573.
Where the compounds of formula I are administered in conjunction with other immunosuppressive immunomodulatory, anti-inflammatory or chemotherapeutic therapy, dosages of the co-administered immunosuppressant, immunomodulatory, anti-inflammatory or chemotherapeutic compound will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a calcineurin inhibitor, on the specific drug employed, on the condition being treated and so forth.
In accordance with the foregoing the present invention provides in a yet further aspect: A method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective non-toxic amount of a compound of formula I and at least a second drug substance, e.g. an immunosuppressant, immunomodulatory, antiinflammatory or chemotherapeutic drug, e.g. as indicated above.
6. A pharmaceutical combination, e.g. a kit, comprising a) a first agent which is a compound of formula I as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent, e.g. an immunosuppressant, immunomodulatory, anti- 0 inflammatory or chemotherapeutic drug, e.g. as disclosed above. The kit may comprise instructions for its administration.
SThe terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single rm 5 patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
00 c The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed C1 and non-fixed combinations of the active ingredients. The term "fixed combination" means 0 10 that the active ingredients, e.g. a compound of formula I and a co-agent, are both c administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of formula I and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of 3 or more active ingredients.
Methodsfor Preparing Compounds of the Invention The present invention also includes processes for the preparation of immunomodulatory compounds of the invention. In the reactions described, it can be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups can be used in accordance with standard practice, for example, see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991.
Compounds of Formula I can be prepared by proceeding as in the following reaction schemes: Reaction Scheme 1
R
1 3
R
13 +1 Pd catalyst R H3C B(OH)2 W R12 H3C- I-R12 ligand R 13 RO R4
R
13 NBS O HO AIBN Br 2) acid or base 00 m) ~wherein n, R 4
R
9
R
2 and R 1 3 are as defined in the Summary of the Invention and SW is a halogen, trifluromethanesulfonate, or the like. The reaction initially proceeds in the C' 5 presence of a catalyst palladium acetate, palladium chloride, palladium bromide, palladium cyanide, palladium acetylacetonate, palladium bis(benzonitrile) dichloride, tris(dibenzylideneacetone)-dipalladium, and the like) and a ligand phosphorous ligands, such as triphenyl phosphine, tri-t-butyl phosphine, 2-(di-t-butylphosphino)biphenyl, dicyclohexylphosphinobiphenyl, and the like) in a solvent tetrahydrofuran, 1,4dioxane, benzene, toluene, xylene, N,N-dimethylformide, N-methyl-pyrrolidinone, and the like) at a temperature of about 20 to about 140 OC and can take up to about 48 hours to complete. The bromination reaction is carried out in the presence of a brominating agent N-bromosuccinimide, bromine, and the like) and a radical initiator 2,2'azobisisobutyronitrile, benzoyl peroxide, and the like). The amination with amino carboxylic esters proceeds in the presence of a base sodium hydride, triethylamine, diisopropylethylamine, potassium carbonate, sodium carbonate, and the like). The subsequent hydrolysis of esters proceeds in the presence of an acid trifluoroacetic acid, hydrochloric acid, and the like) or a base lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, and the like).
Reaction Scheme 2
J
13
R
1 3 Hf
NH
2 R /R1 1) M e OH N H rR13 coupling reagents OH 2) DDQ, CH2C12 0 catalyst. ligand S R13 N R 1 3 R0)O R4 H I NBS 12 0H 3 C R 12 C AI Br AIBN' 2) acid or base S N N R 1 3 c wherein n, R 4
R
9
R
1 2 and R 13 are as defined in the Summary of the Invention and W is a halogen, trifluromethanesulfonate, or the like. The benzoxazole core is formed by the condensation reaction between an appropriate amino phenol and an aldehyde followed by an oxidative cyclization. The coupling reaction proceeds in the presence of a catalyst palladium acetate, palladium chloride, palladium bromide, palladium cyanide, palladium acetylacetonate, palladium bis(benzonitrile) dichloride, tris(dibenzylideneacetone)dipalladium, and the like) and a ligand phosphorous ligands, such as triphenyl phosphine, tri-t-butyl phosphine, 2-(di-t-butylphosphino)biphenyl, dicyclohexylphosphinobiphenyl, and the like) in a solvent tetrahydrofuran, 1,4dioxane, benzene, toluene, xylene, N,N-dimethylformide, N-methylpyroridinone, and the like) at a temperature of about 20 to about 140 °C and can take up to about 48 hours to complete.
Similar transformations as in Reaction Scheme 1 give final compounds of Formula I.
Some compounds of the invention can be prepared by proceeding as in the following reaction schemes: Reaction Scheme 3 N Et 3 N 0 R13 Lawessons reagent H 3 C-t3N H.C0-- C NH 2 C R12DCM '1 XC R 1 2 toluene, microwave 120 0
C
HCR13 K 3 Fe(CN 5 R13 NBS H3CII-RH 2 NaOH, EtOH R 1 2 AIBN
R
13 10), R4 0 R13 0 HO- Nr R12 Br S 2) acId or base Reaction Scheme 4 0 R3 0R 13 1)UAJH 4 H r( Br jeH2) MnO 2 fiIN 1 N R1 2
H
3 Col N.N~ 2 N-6 R- reflux H- 3 C C-6
R
13 HO ~(inNR 4 II H -N R 12 -0 H k NaBH 3
CN
R
13 HO 0 N6 1 n R4
R
4 Reaction Scheme I R 13
R
13 0K R13 Pd catalyst 0 R1 HI ligand H HOyO' R4 NaBH 3
CN
Reaction Scheme 6 0 0 0 tHC HKHka R1 3 KO H R 3 DMSO,1 2 SH3Ci OH
R
OH OH 2 12 A AIBN acceptable acid add 2) acd or basewi R12 12 00 salts of the starting materials or intermediates.
00 CT- wherein n, R 4 R, R 12 and R 3 are as defined in the Summary of the Invention.
Additional Processes for Preparing Compounds of the Invention: A compound of the invention can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound of the invention can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Alternatively, the salt forms of the compounds of the invention can be prepared using salts of the starting materials or intermediates.
The free acid or free base forms of the compounds of the invention can be prepared from the corresponding base addition salt or acid addition salt from, respectively. For example a compound of the invention in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base ammonium hydroxide solution, sodium hydroxide, and the like). A compound of the invention in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid hydrochloric acid, etc.).
Compounds of the invention in unoxidized form can be prepared from N-oxides of compounds of the invention by treating with a reducing agent sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to Prodrug derivatives of the compounds of the invention can be prepared by methods Sknown to those of ordinary skill in the art for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound of the invention with a C 5 suitable carbamylating agent 1,1-acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like).
00 C Protected derivatives of the compounds of the invention can be made by means Sknown to those of ordinary skill in the art. A detailed description of techniques applicable to N the creation of protecting groups and their removal can be found in T W. Greene, "Protecting Groups in Organic Chemistry", 3 rd edition, John Wiley and Sons, Inc., 1999.
c Compounds of the present invention can be conveniently prepared, or formed during the process of the invention, as solvates hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
Compounds of the invention can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to forma pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of the compounds of the invention, dissociable complexes are preferred crystalline diastereomeric salts). Diastereomers have distinct physical properties melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography, or preferable, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from the their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.
In summary, the compounds of Formula I can be made by a process, which C)involves: reaction schemes 1, 2, 3, 4, 5 or 6; and optionally converting a compound of the invention into a pharmaceutically c 5 acceptable salt; optionally converting a salt form of a compound of the invention to a non-salt 00 Mc, form; S(d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide; optionally converting an N-oxide form of a compound of the invention to its unoxidized form; optionally resolving an individual isomer of a compound of the invention from a mixture of isomers; optionally converting a non-derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.
Insofar as the production of the starting materials is not particularly described, the compounds are known or can be prepared analogously to methods known in the art or as disclosed in the Examples hereinafter.
One of skill in the art will appreciate that the above transformations are only representative of methods for preparation of the compounds of the present invention, and that other well known methods can similarly be used.
EXAMPLES
The following examples provide detailed descriptions of the preparation of representative compounds and are offered to illustrate, but not to limit the present invention.
Example 1 3- {[2-(2-Trifluoromethvl-biphenvl-4-vl)-benzo[blthiophen-5-vlmethvll-amino}-propionic.
0 acid
CF
3 00 H02C N To a solution of 5-methylbenzo[b]thiophene (1.0 g, 6.75 mmol) in anhydrous ether C (17 mL) at -78 *C is added n-BuLi (5.1 mL of a 1.52 M solution in hexanes, 7.75 mmol).
The reaction flask is then moved to a 0 *C bath and stirred for 2.5 hours. The mixture is cooled back to -78 and trimethyl borate (1.51 mL, 13.5 mmol) is added neat. The mixture is allowed to warm up to room temperature overnight, and then treated with 2 N HCI mL). After 2 hours, the mixture is extracted with ether (5 and the combined organic solution is dried (MgSO 4 and concentrated. The crude product, thiophenylboric acid, is used without further purification.
To a solution of 5-methylbenzo[b]thiophenylboric acid (0.84 g, 4.4 mmol) in ethanol (2 mL) and toluene (8 mL) is added 2-chloro-5-bromobenzenetrifluoride (1.14 g, 4.4 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.254 g, 0.22 mmol), followed by the addition of a solution of sodium carbonate (1.86 g, 17.6 mmol) in water (8 mL). The mixture is stirred vigorously at 80 0 C for 4 hours, and then filtered through a pad of Celite, which is rinsed with hexanes. The filtrate is concentrated and purified by column chromatography (100% hexanes) to give 1.15 g of 2-(4-chloro-3as a white solid.
To a solution of 2-(4-chloro-3-trifluoromehtylphenyl)-5-methylbenzo[b]-thiophene (0.746 g, 2.28 mmol) in carbon tetrachloride (23 mL) is added N-bromosuccinimide (0.447 g, 2.51 mmol) and 2, 2'-azobisisobuyronitrile (AIBN, 0.075 g, 0.46 mmol). The mixture is stirred at 90 0 C overnight, and then concentrated. The residue is passed through a pad of silica gel, which is further rinsed with hexanes. The combined organic solution is concentrated in vacuo. The resulting crude product, 5-bromomethyl-2-(4-chloro-3trifluromehtylphenyl)benzo[bthiophene, is dissolved in DMF (2 m.L) and added to a pre- 0 stirred suspension of 1-alanine t-butyl ester hydrochloride (0.828 g, 4.56 mmol) and sodium hydride (0.365 g, 60% dispersion in mineral oil, 9.12 mmol) in DMF (4 mL). The mixture is stirred at room temperature for 4 hours, quenched with water (1 mL) and concentrated in 5 vacuo. The resulting residue is purified by column chromatography (50% to EtOAc/hexanes) to afford 0.79 g of 3-{[2-(4-chloro-3- 00 trifluoromethylphenyl)benzo[b] thiophene-5-ylmetyl]amino} propiomec acid t-butyl ester as a yellow solid.
c1 To a solution of the above chloride (0.79 g, 1.68 mmrol) in THE (20 mL) is added 0 10 phenyl boric acid (0.41 g, 3.36 mmol), potassium fluoride (0.39 g, 6.72 mmol), 2- C1 (dicyclohexylphosphino)biphenyl (59 mg, 0. 17 nimol) and palladium (LI) acetate (19 mg, 0.084 mmol). The mixture is stirred at 60 *C under argon for 24 hours. After concentration, the residue is purified by column chromatography (50% to 70% EtOAc/hexanes) to afford 3- {[2-(2-trifluoromethyl-biphenyl-4-yl)benzo thiophen-5-ylmethyl] amino) propionic acid tbutyl ester. The ester is hydrolyzed in TFA-CH 2
CI
2 (1:2 20 mL). The crude product is purified by the preparative LCMS to afford 0.55 g of 3- {[2-(2-trifluoromethylbiphenyl-4-yl)benzo[b] thiophen-5 -yhmethyl] amino) propionic acid, which is converted to the corresponding HCl salt: 'H NMR (400 MHz, CD 3 OD) 65 8.03 1 7.94 (dd, 2 7.92 1 7.42-7.30 (in, 5 7.29-7.21 (in, 2 4.29 2 3.25 2 2.70 2 H); MS (ES) 456.1 (M+H 4 Example 2 3 12-(4-Piperidin- 1 -vl-3 -tri fluoromethvl-phenvF)-benzo[blthiophen-5-ylmethvl1 -amino) propionic acid
CF
3
-S
Piperidine (30 AL, 2.0 minol), Pd 2 dba 3 (2.7 mg, 0.003 inmol), potassium t-butoxide (59 mng, 0.53 mniol) and 1 ,3-bis-(2,6-diisopropylphenyl)-4,5-dihydroimidazol-2-ylidene
HCI
salt (2.6 mg, 0.006 mmol) are added sequentially to a solution of 3- {[2-(4-chloro-3acid tert-butyl ester (72 mg, 0. 15 mmol) in I ,4-dioxane (0.8 mL). The mixture is irradiated in a microwave at 100 C for 1 hour. The reaction is quenched with water and the mixture is concentrated in M 5 vacua. The residue is dissolved in THF and aqueous 2N NaOH (4 mL, 1: 1 and stirred at 60 *C for 3 hours. It is concentrated and purified with preparative LCMS to afford 20 mg 00 Mof 3- {[2-(4-piperidin- 1-yl-3 -trifluoromethyl-phenyl)-benzo[b~thiophen-5-ylmethyl]-amino} propionic acid, which is converted to HCi salt: 'H NMR (400 MHz, CD 3 OD) 5 8.15-8.00 (in, ri 4 7.87 I 7.63 1 7.57 1 4.48 2 3.44 2 3.03 4 2.89 2 1.90-1.80 (in, 4 1.75-1.65 (in, 2 MS (ES) 463.4 Example 3 3- If [2-(2-Trifluoronethl-biphen1-4-y1)-thienof 2.3-blpyridin-5-vlmethyl] -amino I -propionic acid
CF
3 H02C
NS
To a solution of 2-(2-trifluoromethyl-biphenyl-4-yl)-thieno[2,3 carbaldehyde (32 mg, 0.08 3 inmol) in MeCH (2 mL) is added P-alanine HCI salt (37 mg, 0.42 inmol) and triethylamine (23 uL, 0.16 inmol). The mixture is stirred at 50 *C for minutes. Sodium borohydride (30 mg, 0.8 mmol) is added at room temperature and it is stirred for 10 minutes. The mixture is purified with preparative LCMS to give 22 mng of 3- {[2-(2-trifluoroinethyl-biphenyl-4-yl)-thieno[2,3-b]pyridin-5 -ylmethyl] -amino) -propionic acid, which is converted to HCl salt: 'H NMR (400 MHz, CD 3 OD) 6 8.56 I 8.30 1 8.08 I 7.98 (dd, I 7.84 I 7.42 I 7.40-7.34 (in, 3 7.30-7.24 (in, 2 MS (ES) 457.1 SExample 4 C r2-(2-Trifluoromethvl-biphenvl-4-yv)-benzo[b1thiophen-6-ylmethyll-amino} -propionic cacid
F
F
OH
NH 0 s NH SBromoacetaldehyde dimethyl acetal (1.6 mL, 0.01 mol) is added dropwise to a Smixture of m-methylbenzenethiol (1.5 mL, 0.01 mol) and K 2 CO3 (1.66mg, 0.01 mol) in mL acetone at room temperature. The reaction mixture is stirred for 16 hours and then filtered. The solid is washed with acetone, and the combined filtrate and washes are concentrated in vacuo. The residue is diluted with water and extracted with ether. The ether layer is washed with 0.5 M KOH, water, and brine, dried, filtered and concentrated in vacuo to give 2 g yellow oil.
A solution of above yellow oil in CH 2 C2 (20 mL) is added dropwise to a solution of BF 3 in ether (0.7 mL, 0.005 mol) in CH 2 C12 (100 mL) at room temperature. The reaction mixture is stirred for 3 hours, treated with aqueous NaHCO 3 solution and stirred until both phase are clear. The CH 2
CI
2 layer is separated, dried, filtered and concentrated in vacuo to give 0.45 g of an approximately 1:3 mixture of 4- and 6-methyl.benzo[b]thiophene as a dark brown oil. Major isomer: 'H NMR (DMSO-d 6 8 7.78 1H), 7.76 1H), 7.64 1H), 7.39 1H), 7.17 1H), 2.43 3H).
To a solution of 6-methylbenzo[b]thiophene (0.16 g, 0.001 mol) in 10 mL of anhydrous THF at -60 OC is added n-BuLi (0.8 mL, 0.0012 mol) dropwise via syringe.
After stirring for 30 minutes triisopropyl borate (0.3 mL, 0.0012 mol) is added dropwise.
The reaction mixture is allowed to warm to 0 0 C and then partitioned between 1.ON HCI and EtOAc. The organic layer is separated, dried, filtered and concentrated to produce a white solid that is triturated from ether/hexane. Filtration provides 0.17 g of 6-Methylbenzo[b]thiophene-2-boronic acid as white solid. MS m/z 193 [M+1] To a slurry of 6-methyl-benzo[b]thiophene-2-boronic acid (0.19 g, 0.001 mol) in mL of benzene is added 4-bromo-2-trifluoromethyl-biphenyl 0.3g, 0.001 mol). The reaction flask is then covered with aluminum foil to keep out light. To this is added 58 mg of tetrakis(triphenylphosphine-palladium(0), followed by 1 mL of 2.ON sodium carbonate solution. The biphasic mixture is heated at 85'C for 3 hours with vigorous stirring. The mixture is cooled to room temperature and 10 mL of brine solution is added. The organic rrn 5 layer is separated, dried and concentrated under vacuo to afford 0.2g of 6-methyl-2-(2trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophene.
00 M The above product (0.2g, 0.54 mmol) is dissolved in 10 mL Of CCI 4 followed by adding NBS (86 mg, 0.54 mmol) and benzoyl peroxide (24 mg, 0. 1 mmol). The reaction c-i mixture is heated to reflux for 5 hours. After cooling down and removing solvent, the residue is put in column (hexane:EtOAc 95:5). After column, 180mg of 6-bromomethyl-2- CI (2-trifluoromethyl-biphenyl-4-yl)-benzo[b~thiophene is obtained.
To a solution of 6-bromomethyl-2-(2-trifluoromethyl-bipheny1-4-yl)benzo[b]thiophene (I180mg, 0.4 mmol) in 5 mL DMSO, A& 2
CO
3 (330mg, 1.2 mmol) is added. The suspension is heated to 100*C for 3 hours. After work up, the organic layer is dried and concentrated. The residue is applied in column (hexane:EtOAc 9: 1) to afford I100mg of 2-(2-trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophene-6-carbaldehyde as a off white solid. MIS m/z 383[M+1l]+.
To a solution of 2-(2-trifluoromethyl-biphenyl-4-yl)-benzo~lb]thiophene-6carbaldehyde(23 mg, 0.05 mmol) in 3 mL MeOH, f-alanine (8.7mg, 0.1 mmol) and catalytic amount Et 3 N are added. The suspension is heated to 50'C for 0.5 hours, followed by the addition of 2 mg of NaBH 4 After Pre-LC-MS, 10 mg of 3- {[2-(2-trifluoromethyl-biphenyl- 4-yl)-benzo[b]thiophen-6-ylmethyl]-amino-propionic acid is obtained as a white solid. MS m/z 456[M+ I] '11NMIR(MeOD-d 4 8 8.22 I 7.93 (in, 2H), 7.86 111), 7.81 (s, 111), 7.40 (mn, 111), 7.34 111), 7.28 (in, 3H1), 7.24 (in, 2H1), 4.26 211), 3.15 211), 2.52 2H).
Example 3- (r2-(2-Trifluoromethyl-biphenyl-4-fl)-2.3-dihydro- Ct aminolI-propionic acid H
N
00
F
r 5
F
3,4-Bis-bromomethyl-benzoic acid methyl ester (0.32 g, 0.00 1 mol) and 4-bromo- 3-trifluoromethyl-phenylamine (0.72 mL, 0.003 mol) are dissolved in anhydrous 30 mL of EtOH. The reaction mixture is heated to reflux for 3 hours, then cooled down to room temperature. After filtering, a white solid product is obtained. MIS m/z 400 [M+I 2-(4-Bromo-3-trifluoromethyl-phenyl)-2,3-dihydro-l1H-isoindole-5-carboxylic acid methyl ester (0.2 g, 0.0005 mol) is dissolved in 20 mL of anhydrous toluene, followed by adding 40 mg of tetrakis(triphenylphosphine-palladium(0). After bubbling N 2 through the solution for 3 minutes, tributyl-phenyl-stannane (0.22 g, 0.0006 mol) is added to the solution. The reaction mixture is heated to reflux for 16 hours. After column (9:1 Hexane: EtOAc), a white solid product (0.l1 g) is obtained. MS m/lz 398 M+1] 2-(2-Trifluoromethyl-biphenyl-4-yfl-2.3-dihydro- IH-isoindole-5-carboxylic acid methyl ester (0.18 g, 0.0005 mol) is dissolved in 10 mL of anhydrous THF, followed by mL of LAH (0.00 15 mol). The reaction mixture is stirred at room temperature for 5 minutes and quenched with 5% NaOH solution. After workup, organic layer is dried under vacuo and the residue is dissolved in 50 mL of CHC1 3 followed by adding 500 mg of MnO 2 The suspension is stirred at room temperature for 3 hours and followed by filtering. The organic solution is dried and applied to column (4:1 Hexane:EtOAc). After column, a white solid product (40mg) is obtained. MIS m/z 368 To a solution of 2-(2-trifiuoromethyl-biphenyl-4-yl)-2,3 -dihydro- carbaldehyde (19 mg, 0.05 mmol) in 3 mL MeOH, /3-alanine (8.7mg, 0. 1 mmol) and catalytic amount Et 3 N are added. The suspension is heated to 50 00 for 0.5 hours, followed by adding 2 mg of NaBH1 4 After pre-LC-MS, 8 mg of 3- {[2-(2-trnfluoromethyl-biphenyl-4yl)-2,3-dihydro-IH-isoindol-5-ylmethyl]-amino)-propionic acid is obtained as awhite solid.
MS m/z 441[M+1] 'H NMvR (DMS0-l 6 8 7.08-7.26 (in, 9H), 6.80 (brs, 211), 4.53 (s, 4H), 3.68 2H), 2.62 2H), 2.16 2H).
Example 6 3- 1 2-(2-Trifluoromethyl-biphenv-4-yl)-benzooxazol-5-yl- 00 methyll-aminol -propionic acid HO)- A solution of 2-amino-4-methylphenol (1 eti) and 4-chloro-3-trifluoromethylbenzaldehyde (1 eci) in methanol (0.1 M) is heated at SOTC for 30 minutes. After concentration, the residue is dissolved in CH 2 Cl 2 (0.1 M) and treated with DDQ (1.05 eq).
The resulting mixture is stirred at room temperature for 10 minutes. It is then diluted with
CH
2 C1 2 and washed with NaHCO 3 and brine. The organic layer is dried over Na 2
SO
4 After concentration, the desired product is purified by column chromatography EtOAc/hexane) to give a white solid. MS: (ES 4 312.0 A mixture of 2-4clr--rfurmty-hnl--ehlbnoxzl (1 eq), phenyl boronic acid (1.5 eq), Pd(OAc) 2 (0.03 eq), phosphine ligand (0.06 ecij and K.F (3 eq) in dry THF (0.5 M) is heated at 100 0 C in microwave for 30 minutes. The resulting mixture is diluted with EtOAc and washed with brine. The organic layer is dried over Na 2
SO
4 After concentration, the residue is purified by column chromatography EtOAc in hexane) to give the desired product as a white solid. MS: 354.1 A mixture of 5-methyl-2-(2-trifluoromethyl-biphenyl-4-yl)-benzooxazole (1 eq), NBS (1 eq) and AIBN 1 eq) in Gel 4 (0.1 M) is refluxed for 5 hours. After concentration, the desired product is purified by column chromatography (10% EtOAc/hexane). MS: 432.0 To a solution of P-alanine methyl ester hydrochloride salt (2 eq) in dry DMF M) is added NaH (3.5 eq). After stirring at room temperature for 10 minutes, a solution of bromomethyl-2-(2trifluoroinethyl-bipheny4-yl)bezooxazole (I eq) in dry DMF (1 M) is added. The resulting mixture is stirred at room temperature for 2 hours. It is diluted with 0 H 2 0 and extracted with EtOAc. The organic solution is washed with brine and dried over Na 2
SO
4 After concentration, the residue is dissolve in MeOH (0.2 M) and treated with 2N LiOH solution (3 eq) for 10 hours. The final compound is purified by preparative LCMS to r 5 give 3- {[2-(2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-5-ylmethyl]-amino}-propionic acid; 'H NMR (400 MHz, CD30D) 8 2.74 J= 6.7 Hz, 2H), 3.30 J= 6.8 Hz, 2H), 4.39 2H), 7.34 2H), 7.43 3H), 7.57 2H), 7.78 J= 8.3 Hz, 1H), 7.94 1H), S8.43 J= 8.0 Hz, 1H), 8.59 1H). MS: (ES 1 441.3 (M+1) 0 10 Example 7 1-[2-(4-Isobutvl-3-trifluoromethvl-phenyl)-benzooxazol-6-vlmethyll-azetidine-3-carboxylic acid
CF
3 H O 0
N
A mixture of [2-(4-chloro-3-trifluoromethyl-phenyl)-benzooxazol-6-yl]-methanol (1 eq) and Pd(PBu' 3 2 (0.05 eq) is treated with isobutyl zinc bromide in THF (0.5 M, 3 eq).
The resulting mixture is heated at 100 OC in microwave for 30 minutes. The reaction mixture is diluted with aqueous HCI and extracted with EtOAc. The organic solution is washed with brine and dried over Na 2
SO
4 After concentration, the residue is purified by flash column chromatography (30% EtOAc in hexane) to give the desired intermediate isobutyl-3-trifluoromethyl-phenyl)-benzooxazol-6-yl]-methanol. MS: 350.1 To a solution of [2-(4-isobutyl-3-trifluoromethyl-phenyl)-benzooxazol-6-yl]methanol (1 eq) in dioxane (0.2 M) is treated with MnO 2 (10 eq). The resulting mixture is refluxed for 20 minutes and filtered through celite. After concentration, the residue is redissolved in MeOH (0.2 M) and is added azetidine-3-carboxylic acid (2 eq) and Et 3 N (1.8 eq). The resulting mixture is heated at 50C for 1 hour. After cooling to room temperature, NaBH 3 CN (3 eq) is added in portions. The final compound is purified by preparative LCMS. 'H NMR (400 MHz, CD30D) 5 8.49 1H), 8.38 J= 8.4 Hz, 1H), 7.88 1H), 7.84 J=8.4 Hz, 111), 7.66 J 8.4 Hz, 111), 7.52 J=8.4 Hz, IHf), 4.57 2H), 4.34 (in, 4H), 3.70 (in, I 2.76 J 6.8 Hz, 2H), 2.03 (in, I1H), 0.95 J 7.2 Hz, 6H1). MS: 433.2 Example 8 00 3- (2-Trifluoromethl-biphenl-4-yi)-benzofuran-5-lmethlI -amino) -propionic acid c-i CF 3 H0 2 To a solution of 4-hydroxy-3-iodobenzaldehyde (I eq) and 1-chloro-4-ethynyl-2trifluoromehitylbenzene (1 eq) in DMF (0.2 M) is added copper(I) iodide (0.1 eq), dichlorobis(triphenylphosphine)palladium(II) 1 eq) and diisopropylethylamine (3 eq).
The mixture is irradiated with microwave at 80 *C for 10 minutes. The product, 2-(4-chloro- 3-trifluoromethyl-phenyl)-benzofuran-5-carbaldehyde, is purified with column chromatography.
To a solution of 2-(4-chloro-3-trifluoromethyl-phenyl)-benzofuran-5-carbaldehyde (1 eq) in CH 3 0H (0.2 M) is added P-alanine t-butyl ester (2.5 eq) and triethylamine (2 ecO.
The mixture is stirred at 50 0 G for 30 minutes. Sodium borohydride (5 eq) is then added at room temperature and the mixture is stirred for 10 minutes. The product, 3-(2-(4-chloro-3- -amnino} -propionic acid tert-butyl ester, is purified with column chromatography.
To a solution of 3- {[2-(4-chloro-3-trifluoroinethyl-phenyl)-benzofuran-5 ylmethyl] -amino)}-propionic acid tert-butyl ester (I eci) and phenyl boric acid (1.5 eq) in THE (0.5 M) is added palladium(II) acetate 1 ecO, 2-(dicyclohexylphosphino)biphenyl (0.2 eq) and potassium fluoride (4.0 eq). The mixture is irradiated with microwave at 120 0
C
for 45 minutes. The product, 3- [2-(2-tnifluoroinethyl-biphenyl-4-yl)-benzofuran-5ylmethyl] -amino)}-propionic acid tert-butyl ester, is purified with column chromatography.
The ester is hydrolyzed with TFA in CH 2 Gl 2 v/v) at room temperature. It is purified with preparative LCMS to afford 3- {[2-(2-trifluoromethyl-biphenyl-4-yl)-benzofuran-5ylmethyl] -amino)}-propionic acid, which is converted to HC1 salt: 'H NMR (400 MHz,
CD
3 OD) 6 8.29 1 8.18 (dd, 1 7.82 1 7.71 I 7.55-7.30 (in, 8 4.36 2 3.32 2 2.77 2 MS (ES) 440.2 Example 9 00 3- f f 2-2-Tri fluoromethyl-biphenyl-4-yl'I-benzothiazol1-6-vlmethyll -amino 1propionic acid
CF
3
N
H HOrN 14 0 To a solution ofp-toluidine (0.44 g, 4.1 inmol) in 10 ml of CH 2
CI
2 (pre-cooled to 0 0 C) are added Et 3 N 14 ml, 2 eq.) and 4-chloro-3-trifluoromethyl-benzoyl chloride (1 g, 4.1 mrnol) in 5 ml of CH 2 Cl 2 The mixture is slowly warmed to room temperature and continued to stir at room temperature for an hour. The mixture is diluted with 50 ml of
CH
2 Cl 2 washed with IN HCI solution, and brine. The organic layer is separated, dried over MgSO 4 filtered, and concentrated. The residue is purified by column chromatography (EtOAc/Hexanes, 2:3) to give 1.25 g of 4-chloro-N-p-tolyl-3-trifluoromethylbenzaxnide.
4-chloro-N-p-tolyl-3-trifluoromethyl-benzamide (1.0 g, 3.19 mmol), Lawesson' s reagent (774 mng, 0.6 eq.) and toluene (2.5 mL) is mixed in a microwave vial. The mixture is heated to 120 TC for 1000 seconds using microwave irradiation. The mixture turned into clear solution. Ether (50 ml) is added to dilute the reaction mixture. The solution is then washed with brine, dried over MgSO 4 filtered and concentrated. The mixture is purified by column chromatography (EtOAc/Hexanes=5/95) to afford 970 mg of 4-chloro-N-ptolyl-3-trifluoromethyl-thiobenzamide as a yellow solid.
To 2M aqueous solution K 3 Fe(CN) 6 (4 mL, 8 inmol) (pre-heated to 90*C) is added dropwise to a suspension of 4-chloro-N-p-tolyl-3-trifluoromethyl-thiobenzamide (660 mng, 2 rmnol) in 2M NaOH (9 ml) and EtOH (3 ml). The mixture is heated at 90 0 C overnight. The mixture is cooled to room temperature and extracted with EtOAc (50 mlx2). The combined organic layers are washed with brine, dried over MgSO 4 filtered and concentrated. The mixture is purified by ISCO system (EtOAc/Hexanes: 20 minutes run 0 to 100% of EtOAc).
2-(4-Chloro-3-trifluoromethyl-phenyl)-6-methylbenzothiazole is isolated (170 mg, as e 5 well as 380 mg of the starting material.
A microwave vial is charged with 2-(4-chloro-3-trifluoromethyl-phenyl)-6- 00 methylbenzothiazole (170 mg, 0.519 mmol), phenylboronic acid (95 mg, 1.5 KF mg, 3 Pd(OAc) 2 (6 mg, 5 mol (dicyclohexylphosphino)biphenyl (18 mg, 10 mol 0 and THF (0.5 mL). The mixture is heated to 120 0C for 30 minutes using microwave S 10 irradiation. The mixture is then filtered through celite and washed with EtOAc. The filtrate Cl is concentrated and purified by column chromatography (EtOAc/Hexane, 5/95) to give 120 mg of 6-methyl-2-(2-trifluoromethyl-biphenyl-4-yl)benzothiazole.
To a solution of 6-methyl-2-(2-trifluoromethyl-biphenyl-4-yl)benzothiazole (120 mg, 0.325 mmol) in CC14 (3.5 ml) is added NBS (64 mg, 1.1 The mixture is heated to reflux for 15 minutes before AIBN (5 mg, 0.1 eq.) is added. The reaction is refluxed overnight, filtered through celite and washed with CCl4. The filtrate is concentrated and purified by column chromatography (EtOAc/Hexane=9/95). 6-Bromomethyl-2-(2trifluoromethyl-biphenyl-4-yl) benzothiazole (105 mg, 72%) is isolated.
To a solution of J-alanine tert-butyl ester hydrochloride (47 mg, 1.1 eq.) in DMF (2 mi) is added NaH (60% in mineral oil) (28 mg, 3 eq.) at room temperature. The mixture is stirred at room temperature for 15 minutes before a solution of 6-bromomethyl-2-(2trifluoromethyl-biphenyl-4-yl)benzothiazole (105 mg, 0.234 mmol) in DMF (1 mi) is added.
The mixture is stirred at room temperature overnight, diluted with EtOAc, washed with Na2S 2 0 3 brine, dried over MgSO 4 filtered and concentrated. Column chromatography
(CH
2 Cl 2 /CH30H, 95/5) gave 31 mg of3- {[2-(2-trifluoromethyl-biphenyl-4-yl)benzothiazol-6-ylmethyl]-amino) -propionic acid tert-butyl ester.
3- [2-(2-Trifluoromethyl-biphenyl-4-yl)-benzothiazol-6-ylmethyl] -amino propionic acid tert-butyl ester (31 mg, 0.0605 mmol) is dissolved in TFA/CH 2
CI
2 (1/1)(1 mnL). The solution is stirred at room temperature for an hour. The mixture is concentrated and purified by reversed phase preparative LC/MS to give 10 mg of 3- trifluoromethyl-biphenyl-4-yl)-benzothiazol-6-ylmethyl]-amino} -propionic acid: 'H NMR
(CD
3 OD, 400 MHz) 5 8.54 I 8.35 1 8.22 1 8.18 2 7.68 I H), 7.45 (in, 3 7.37 (mn, 2 4.44 2 3.36 (in, 2 2.80 (in, 2 MS 457.0
(M+H
4 Example 003- jr3-Chloro-2-(2-trifluoromethl-bipheny-4-yl)-benzo [blthionhen-5-ylinethyll-amninol propionic acid N- CF 3 HO
NH
(14 /j To a solution of 5-methyl-2-(2-trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophene (14mg, 0. 5 nimol) in CHC1 3 (2.5 inL) is added S0 2 01 2 (44 ptL, 1. 1 The mixture is heated to reflux overnight (about 14 hours). All the solvent is removed under reduced pressure. The residue is extracted with CH 2 Cl 2 (50 mL), washed with saturated aqueous NaHCO 3 brine, dried over MgSO 4 filtered, and concentrated to give an oil. The mixture is purified by column chromatography (EtOAc/Hexane, gradient) to give 112 mg of 3-chloro- 5-inethyl-2-(2-trifluoroinethyl-biphenyl-4-yl)-benzo[b]thiophene in 56% yield.
To a solution of 3-chloro-5-methyl-2-(2-trifluoromethyl-biphenyl-4-yl)benzo[b]thiophene(1 10 mng, 0.273 inmol) in CC14 (3 ml) is added NBS (49 mg, I The mixture is heated at reflux for 15 minutes before AIBN (4.5 mg, 0. 1 eq.) is added. The reaction is further heated at reflux overnight. The mixture is filtered through Celite and washed with CCLI. The filtrate is concentrated and purified by column chromatography (EtOAc/Hexane, gradient) to give 50 mng of 5-broinomethyl-3-chloro-2-(2-trifluoromethylbiphenyl-4-yl)-benzo[b]thiophene in 38% yield.
To a solution of 5-bromoinethyl-3-chloro-2-(2-trifluoroinethyl-biphenyl-4-y)benzo[b]thiophene (50 ing, 0.104 minol) in DMF (1 mL) are added P-alanine tert-butyl ester hydrochloride (19 mg, I eq.) and K 2 C0 3 (68 mg, 5 The mixture is stirred at 50 0
C
overnight. The mixture is diluted with EtOAc (40 inL), washed with 10% aqueous Na 2
S
2
O
3 brine, dried over MgSO 4 filtered, and concentrated. The mixture is purified by column chromatography (EtOAc/Hexane, gradient) to give 43 mg of 3-{[3-chloro-2-(2tri fluoromethyl-biphenyl-4-yl)-benzo[b] thiophen-5 -ylmethyl] -amino) -propionic acid tertbutyl ester in 76% yield.
3- {[3-Chloro-2-(2-trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophen-5-ylmethyl]- 5 amnino)-propionic acid tert-butyl ester (43 mg, 0.079 mmol) is dissolved in TFA/CH 2 Cl 2 (1 mL). The solution is stirred at room temperature for an hour. The mixture is 00 M concentrated and purified by reversed phase preparative LC/MS to give 23 mg of 3 chloro-2-(2-trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophen-5 -ylmethyl] -amnino) -propionic (Ni acid: 1'H NMR (CD 3 OD, 400 NMz) 8 8. 10 1 7.96-8.02 (in, 3 7.54 I 7.46 1 7.35-7.37 (in, 3 7.28-7.29 (in, 2 4.37 2 3.26(m, 2 2.71 (mn, 2 H), MS 490.3 By repeating the procedure described in the above examples, using appropriate starting materials, the following compounds of Formula I are obtained as identified in Table 1.
TABLE 1 00 Structure 00 00 Structure 00 Structure 00 Structure Physical Data Compound IStructure MS ES aN
CF
3 79 469.2 00 00 HO H 491CF2 HN(N 49.
CF
3 c-I
N
8N 447.2 HO)<(JN 0_ 82 HOs. )LL~ 421.2 N N
CF
83HO 481.1
F
C F 3 491 84 HO H91.1
O
HON N CF 3 46.
H 'N1 6.
H~NN
87 HO 469.2 00 HO~~ N
F
3 88 HO H /6950.2 _0 0 3
C
C F 3
F
HO
H
89 49.
H
3 CO 49QF Structure 00 Physical Compound Structure Data MS ES CI (M +l)
HO
113 0455.2 113 0 N C 3
HOH
00O 114 0j-N 0 456.2 0 N N CF 3 116 H0468.1 117 -N468.1 118 0480.1
HO,
HOOC,- N 0 119 H I492.2
-S
121 N0-1 464.2 HOOC 52 Structure H0 2
C
00 M 130 HO 2 C
H
Example 11 Compounds of Formula I Exhibit Biological Activity A. In vitro: GPCR activation assay measuring GTP [Y- 35 S1 binding to membranes prepared from CHO cells expressing human EDG receptors EDG-1 (S1PI) GTP [y- 35 S] binding assay: Homogenized membranes are prepared from CHO cell clones stably expressing a human EDG-1 N-terminal c-myc tag. Cells are grown in suspension in two 850 cm 2 roller bottles for three or fours days before harvesting.
The cells are centrifuged down, washed once with cold PBS, and resuspended in 20 ml of Buffer A (20 mM HEPES, pH 7.4, 10 mM EDTA, EDTA-free complete protease inhibitor cocktail [1 tablet/25 The cell suspension is homogenized on ice, using a Polytron homogenizer at 30000 rpm at three intervals of 15 seconds each. The homogenate is first centrifuged at 2000 rpm on a tabletop low speed centrifuge for 10 minutes. The supematant, after passing through a cell strainer, is then re-centrifuged at 50,000 x g for 25 minutes at 4°C. The pellet is resuspended into buffer B (15% glycerol, 20 mM HEPES, pH 7.4, 0.1 mM EDTA, EDTA-free complete protease inhibitor cocktail [1 tablet/10 Protein concentration of the prep is determined using the BCA Protein Assay kit (Pierce) using BSA as standard. The membranes are aliquoted and kept frozen at -80 0
C.
Solutions of test compounds ranging from 10mM to 0.01nM are prepared in DMSO. SIP is diluted in 4% BSA solution as positive controls. The desired amount of membrane prep is diluted with ice-cold assay buffer (20 mM HEPES, pH 7.4, 100 mM r NaCl, 10 mM MgCl 2 0.1% Fatty acid-free BSA, 5 pM GDP) and vortexed well. 2 Il or Sless of compound is distributed into each well of a round-bottom 96-well polystyrene assay plate, followed by addition of 100 pI of diluted membranes (3-10 pg/well) and kept on ice until the addition of hot GTPyS. 35 S]-GTPyS is diluted 1:1000 with cold assay buffer 5 and 100 ul is added into each well. The reaction is carried out at room temperature for minutes before the membranes are harvested onto Perkin-Elmer Unifilter® GF/B-96 filter 00 Splate using a Packard Filtermate Harvester. After several washes with wash buffer (20 mM SHEPES, pH 7.4, 100 mM NaCI, 10 mM MgCI 2 and a rinse with 95% ethanol, the filter is
C
I dried in a 37'C oven for 30 minutes. MicroScint-20 is added and the plate sealed for scintillation counting on TopCount. EC50 values are obtained by fitting the GTP [y-PS]
C
binding curves (raw data) with the dose response curve-fitting tool of GraphPad Prism. Six or twelve different concentrations are used to generate a concentration response curve (using three data points per concentration).
EDG-3,-5,-6 and -8 GTP [y- 5 S] binding assays are carried out in a comparable manner to the EDG-1 GTP [y- 3 S] binding assay using membranes from CHO cells stably expressing c-terminal c-myc tagged or untagged receptors. For each membrane preparation, titration experiments are first run with SIP control to determine the optimal amount of membranes to be added per assay well. Compounds of the invention were tested according to the above assay and were observed to exhibit selectivity for the EDG-1 receptor. For example, 3- {[2-(2-trifluoromethyl-biphenyl-4-yl)-benzo[]thiophen-5-ylmethyl]-amino)propionic acid (example 1) has an ECso of 0.6 nM in the above assay and is at least 1000 fold selective for EDG-1 compared to one or more of the other receptors including EDG-3, EDG-6 and EDG-8.
B. In vitro: FLIPR calcium flux assay Compounds of the invention are tested for agonist activity on EDG-1, EDG-3, EDG-5, and EDG-6 with a FLIPR calcium flux assay. Briefly, CHO cells expressing an EDG receptor are maintained in F-12K medium (ATCC), containing 5% FBS, with 500ug/ml of G418.
Prior to the assay, the cells are plated in 384 black clear bottom plates at the density of 10,000 cells/well/25 l in the medium of F-12K containing 1% FBS. The second day, the cells are washed three times (25 pl/each) with washing buffer. About 25 pl of dye are added to each well and incubated for 1 hour at 37 0 C and 5% CO 2 The cells are then washed four
O
0 times with washing buffer (25 il/each). The calcium flux is assayed after adding 25 ul of SEQ2871 solution to each well of cells. The same assay is performed with cells expressing c. each of the different EDG receptors. Titration in the FLIPR calcium flux assay is recorded 5 over a 3-minute interval, and quantitated as maximal peak height percentage response relative to EDG-1 activation.
00 C C. In vivo: Screening Assays for measurement of blood lymphocyte depletion and assessment of heart effect C Measurement ofcirculating lymphocytes: Compounds are dissolved in DMSO and 0 10 diluted to obtain a final concentration of 4% DMSO final concentration) and then CNI further diluted in a constant volume of Tween80 25%/H20, v/v. Tween80 25%/H20 (200 gl), 4% DMSO, and FTY720 (10lg) are included as negative and positive controls, respectively. Mice (C57bl/6 male, 6-10 week-old) are administered 250-300 p.L of compound solution orally by gavages under short isoflurane anesthesia.
Blood is collected from the retro-orbital sinus 6 and 24 hours after drug administration under short isoflurane anesthesia. Whole blood samples are subjected to hematology analysis. Peripheral lymphocyte counts are determined using an automated analyzer. Subpopulations of peripheral blood lymphocytes are stained by fluorochromeconjugated specific antibodies and analyzed using a fluorescent activating cell sorter (Facscalibur). Two mice are used to assess the lymphocyte depletion activity of each compound screened. The result is an EDso, which is defined as the effective dose required displaying 50 of blood lymphocyte depletion. Compounds of the invention were tested according to the above assay and were preferably found to exhibit an EDso of less than Img/kg, more preferably an EDso of less than 0.5 mg/kg. For example, trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophen-5-ylmethyl]-amino} -propionic acid (example 1) exhibits an ED50 of 0.2 mg/kg.
Assessment of Heart Effect: The effects of compounds on cardiac function are monitored using the AnonyMOUSE ECG screening system. Electrocardiograms are recorded in conscious mice (C57bl/6 male, 6-10 week-old) before and after compound administration. ECG signals are then processed and analyzed using the e-MOUSE software.
jg of compound further diluted in 200pl water, 15% DMSO are injected IP. Four mice Care used to assess the heart effect of each compound.
c D: In vivo: Anti-angiogenic Activity SPorous chambers containing sphingosine-1-phosphate (5 M/chamber) or (ii) human VEGF (1 Gtg/chamber) in 0.5 ml of 0.8% w/v agar (containing heparin, 20 U/ml) are 0o implanted subcutaneously in the flank of mice. SIP or VEGF induces the growth of m vascularized tissue around the chamber. This response is dose-dependent and can be 0 quantified by measuring the weight and blood content of the tissue. Mice are treated once a day orally or intravenously with a compound of formula I starting 4-6 hours before implantation of the chambers and continuing for 4 days. The animals are sacrificed for measurement of the vascularized tissues 24 hours after the last dose. The weight and blood content of the vascularized tissues around the chamber is determined. Animals treated with a compound of formula I show reduced weight and/or blood content of the vascularized tissues compared to animals treated with vehicle alone. Compounds of Formula I are antiangiogenic when administered at a dose of about 0.3 to about 3mg/kg.
E: In vitro: Antitumor Activity A mouse breast cancer cell line originally isolated from mammary carcinomas is used, e.g. JygMC(A). The cell number is adjusted to 5x10 5 for plating in fresh medium before the procedure. Cells are incubated with fresh medium containing 2.5mM of thymidine without FCS for 12 hours and then washed twice with PBS, followed by addition of fresh medium with 10% FCS and additionally incubated for another 12 hours. Thereafter the cells are incubated with fresh medium containing 2.5mM of thymidine without FCS for 12 hours.
To release the cells from the block, the cells are washed twice with PBS and replated in fresh medium with 10% FCS. After synchronization, the cells are incubated with or without various concentrations of a compound of formula I for 3, 6, 9, 12, 18 or 24 hours. The cells are harvested after treatment with 0.2% EDTA, fixed with ice-cold 70% ethanol solution, hydrolyzed with 250p.g/ml of RNaseA (type 1-A: Sigma Chem. Co.) at 37 0 C for 30 minutes and stained with propidium iodide at 10mg/ml for 20 minutes. After the incubation period, the number of cells is determined both by counting cells in a Coulter counter and by the SRB Scolorimetric assay. Under these conditions compounds of formula I inhibit the proliferatior of the tumor cells at concentrations ranging from 10-12 to 10 6
M.
It is understood that the examples and embodiments described herein are for 00 0 5 illustrative purposes only and that various modifications or changes in light thereof will be Ssuggested to persons skilled in the art and are to be included within the spirit and understanding of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
-58-

权利要求:
Claims (12)
[1] 1.A compound of Formula 1: R 6 R 5 R 3 R 2 R 8 R 7 in which: n islIor 2; A is chosen from -C(O)ORg, OP(O)(0R 9 2 P(O)(OR9) 2 -S(0) 2 0R 9 P(O)(Rg)ORq and IH-tetrazol-5-yl; and Rg is chosen from hydrogen and CI. 6 alkyl; X is a band or is chosen from Cl-4alkylene, -XIOX 2 -X 1 NR, 0 X 2 XIC(O)NRIOX 2 -XINRIOC(O)X 2 -XIS(O)X 2 -XIS(O) 2 X 2 -XISX 2 and C 2 9 heteroarylene; wherein X, and X 2 are independently chosen from a bond and C I 3 alkylene; Rio is chosen from hydrogen and C 1 -6alkyl; and any heteroarylene of X is optionally substituted by a member of the group chosen from halo and C, 4 6alkyl; Y is a fused 5,6 or 6,6 hetero bicyclic ring system consisting of at least one aromatic ring, wherein said fused bicyclic ring system of Y can be optionally substituted with I to 3 radicals chosen from halo, hydroxy, cyano, nitro, CI-6alkyl, CI-6alkoxy, halo- substituted C 1 6alkyl and halo-substituted C 1 .6alkoxy; R, is chosen from C 6 4oaryl and C 2 9 heteroaryl; wherein any aryl or heteroaryl of R, is optionally substituted by a radical chosen from C6-10arylCO-4alkyl, C 2 .gheteroaryCO.. 4 alkyl, C3-Scycloalky1Co-4alkyl, C 3 -sheterocycloalkylCo.4ialkyl or CI-6alky1; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R, can be optionally substituted by I to 3 radicals chosen from halo, CI-6alkyl, C,-6alkoxy, halo-substituted-CI-6alkyl and halo- substituted-C 14 alkoxy; and any alkyl group of R, can optionally have a methylene replaced by an atom or group chosen from -S(0) 2 -NRIO- and wherein RIO is chosen from hydrogen or C 1 -6alkyl; R 2 R 3 R 5 R. 6 R7 and Rg are independently chosen from hydrogen, C 1 6 alkyl, halo, hydroxy, C 14 6alkoxy, halo-substituted C 1 -6alkyl and halo-substituted CI.6alkoxy; 00 010 R4 is chosen from hydrogen and C 1 -alkyl; or R 7 and either R 2 R 4 or Rs together with the atoms to which R 2 R 4 R 5 and R 7 are attached forms a 4 to 7 member ring; wherein said 4 to 7 member ring is saturated or partially unsaturated; and the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.
[2] 2. The compound of claim I in which R, is phenyl, naphthyl. furanyl, or thienyl optionally substituted by C 6 -loarylCo-4allcyl, C 2 9 heteroarylCO-4alkyl, C 3 -scycloalkyCo4alkyl, C 3 -gheterocycloalkylCo4alkyl or C 1 6alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R, can be optionally substituted by one to five radicals chosen from halo, C 1 6 alkyl, C 1 6 alkoxy, halo-substituted-C 1 6alkyl and halo-substituted-C 6 alkoxy; and any alkyl. group of R, can optionally have a methylene replaced by an atom or group chosen from -S(0) 2 -NRIO- and wherein Rio is hydrogen or C 1 -6alkyl.
[3] 3. The compound of claim I in which Y is chosen from: N R 11 N N C0/4; N: L.. N N N N S 0 and L' 0 wherein R 1 is hydrogen or Ci-6alkyl; and the left and right asterisks of Y indicate the point NI of attachment between either -C(R 2 )(R 3 and X of Formula I or between X and S C(R 2 )(R 3 of Formula I, respectively; and Y can be optionally substituted with 1 to 3 0radicals chosen from halo, hydroxy, cyano, nitro, Ci. 6 alkyl, C 1 6 alkoxy, halo-substituted CI. 6 alkyl and halo-substituted Ci-6alkoxy. 00 c
[4] 4. The compound of claim 1 in which RI is chosen from: R" l and R 3 wherein the asterisk is the point of attachment of Ri with X; m is chosen from 1 and 2; R 1 2 is hydrogen, C6-loarylCo4alkyl, C 2 9 heteroarylCo 4 alkyl, C3. 8 cycloalkylCo 4 alkyl, C 3 .sheterocycloalkylCo-4alkyl or C 1 6 alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R 12 can be optionally substituted by one to three radicals chosen from halo, Cisalkyl, Ci.6alkoxy, halo-substituted-Ci- alkyl and halo-substituted-Ci. 6 alkoxy; and any alkyl group of Ri 2 can optionally have a methylene replaced by an atom or group chosen from -S(O) 2 -NRio- and wherein Rio is hydrogen or Ci~-alkyl; and R 13 is chosen from halo, C 1 6 alkyl, Cl6alkoxy, halo-substituted-Ci-6alkyl and halo- substituted-C 1 .alkoxy.
[5] The compound of claim 1 in which A is -C(O)OH; R 2 R 3 Rs, R 6 and R 8 are hydrogen; R 7 is chosen from hydrogen and fluoro; R4 is chosen from hydrogen and CI. 6 alkyl; or R 7 and R 4 together with the atoms to which R 7 and R 4 are attached forms azetidine.
[6] 6. The compound of claim 5 in which Y is chosen from: N N SNr S N 0 wherein R i is hydrogen or C 16 alkyl; and the left and right asterisks of Y indicate the point of attachment between either -C(R 2 )(R 3 and X of Formula I or between X and C(R 2 )(R 3 of Formula 1, respectively; and Y can be optionally substituted with 1 to 3 radicals chosen from chioro, fluoro, methyl, ethyl, cyano and bromo.
[7] 7. The compound of claim 6 in which Xis chosen from a bond, -NH- and N(CH 3 and R, is chosen from: (R12) (R130 an (R 13)c--S and 4 M;L wherein m is chosen from I and 2; R 12 is hydrogen, phenyl, piperidinyl, 2-methyl- butyl, 3-methyl-butyl, cyclohexyl, cyclohexyl-oxy, cyclopentyl-oxy, sec-butoxy, tetrahydropyranyl, phenoxy, benzo[ I,3]dioxolyl, naphthyl, 2,2-dimethyl-pentyl, butyl, benzo[b]furanyl, benzyl, phenethyl, phenyl-ethenyl, I1-phenyi-ethyl and cyclopropyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R 12 can be optionally substituted by one to three radicals chosen from fluoro, isobutyl, 2-methyl-butyl, trifluoromethyl, chioro, methyl, trifluoromethoxy and methoxy; and R 13 is chosen from trifluoromethyl, trifluoromethoxy, methyl, fluoro, chioro and methoxy.
[8] 8. The compound of claim 7 chosen from: 3- {[2-(2-trifluoromethyl-biphenyl- ri 4-yl)-benzo[b] thiophen-5-ylmethyl] -amino) -propionic acid, 3- {[2-(4-piperidin- 1 -yl- 3 tri fluoromethyl-phenyl)-benzo thiophel- 5 -ylmethyl] -amino)} -propionic acid, 3- Tri fluoromethy -bipheny-4-yi) -th-deflo[2,3 -b ]pydi- 5 -ylmethyll amino}I -prop ionic acid, 3- {I2(2Trifluoromethyl-biphefl-4-y)-benzo[b]thiophen-6-ylmethyl] -amino) -propionic 00 acid, 3 [2-(2-Tri fluoromethy-b ipheny-4-yl)-2,3 -dihydro- I H-isoindol- 5-ylmethyl ]-amino)} propionic acid, 3-1{[2-(2-Tri fluoromethyl-biphenyl-4-yI)-benzooxazol-5-ylmethyl] -amino) propionic acid, I -[2-(4-Isobutyl-3-trifluoromethy1-pheny)-benzooxazo-6-ylmethy1]- C azetidine-3-carboxylic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4-yl)-belzofural-5 0 10 ylmethyl] -amino) -propionic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4-yl)-belzothiazol-6- ylmethyl] -amino) -propionic acid, 3- {[3-Chloro-2-(2-trifluoromethyl-biphenyl-4-yl)- benzo [b]thiophen-5 -ylmethyl] -amino)} -propionic acid, I -[2-(2-Trifluoromethyl-biphenyl-4- yl)-benzo[blthiophen-5-ylmethyl]-azetidine-3 -carboxylic acid, 3- {[2-(2'-Fluoro-2- tri fluoromethyl-biphenyl-4-yl)-benzo [bl thiophel-5 -ylmethyl] -amino)I -prop ionic acid, 3-1{[2- (5 -Fluoro-2-tri fluoromethyI-biphenyl-4-yl)-benzo thiophen-6-yl methyl] -amino)} -propionic acid, 3- {[3-Fluoro-2-(2-tri amino) -propionic acid, 3- {[2-(4-Cyclohexyl-3 -trifluoromethyl-phenyl)-benzo[b]thiophefl-S- ylmethyl] -amino}I -propionic acid, 3- {[4-Chloro-2-(2-trifluoromethyl-bipheflyl-4-yI)- -amino) -propionic acid, I -[2-(4-Cyclohexyl-3 trifluoromethyl-phenyl)-belzo[b] thiophen-5 -ylmethyl]-azetidine-3 -carboxylic acid, 3- Methoxy-2-(2-tri fluoromethy1-biphelyl-4-y1)-beflzo[b] thioPhen-5 -ylmethyl] -amino)} propionic acid, 3- {[6-Chloro-2-(2-trifluoromethyl-biphenyl-4-yl)-belzo[b]thiophefl5- ylmethyl] -amnino) -propionic acid, 3- {[2-(4-Gyclopentyloxy-3 -trifluoromethyl-phenyl)- benzo [b]lthiophen- 5-yhmethyl] -aminlo) -propionic acid, 3- {[2-(4-sec-Butoxy-3- tri fluoromethyl-phenyl)-benzo thiophel-5 -ylmethyl] -amino -prop ionic acid, 3-1{[2-(4-sec- Butyl-3-tri fluoromethyl-phenyl)-benzolb]thiophen-5-ylmethyl] -amino) -propionic acid, 3- [2-(4-Isobutyl-3 -tri fluoromethyl-phenyl)-benzollb]thiophen-5 -ylmethylI -amino) -propionic acid, 3- {[2-(4-Cyclohexyloxy-3-tri fluoromethyl-phenyl)-benzo[b]thiophel-5 -ylmethyl] amino) -propionic acid, {2-[4-(Tetrahydro-pyran-4-yl)-3 -trifluoromethyl-phenyl]- benzollb]thiophen-5-yTIethyl) -amino)-propionic acid, 3- {[3-Methyl-2-(2-tri fluoromethyl- -ylmethyl)-amino) -propionic acid, 3- ([3-Cyano-2-(2- trifuormetyl-iphnyt4-y)-bnzob~tiopen- -ymetyl]-amno)-propionic acid, 3- Naid 3-((3Fromo-5-trifluoromethy1-phel4y1)-beflzo[b]thiophel-5 -ylmethyl] -amino) -poi poncacid, 3- {[2-(2-Fluoro-3 -trifluoromethyl-phenyl)-benzo[b]thiophe5-YlmethY i)- M 5 amnino} -propionic acid, 3- {[2-(2-Trifluoromethyl-phenyl)-benzo[b]thiophel-5-ylmethyl]- 00 amino) -propionic acid, I -[2-(2-Trifluoromethyl-biphelyl-4-y1)-benzo[b]thiophenm4- ylmethyljj-azetidine-3-carboxylic acid, 3- {[2-(4-Chloro-3-trifluoromethyl-phenyl)- benzo thiophen-5 -ylmethyl] -aminlo) -propionic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4- y1)-benzo[b]thiophen-4-ylmethy1]-aiflilo) -propionic acid, 3- -Bis-trifluoromethyl- C) 10 phenyl)-benzo[blthiophefl-5 -ylmethyl] -amino) -propionic acid, 3-({12-(2-Methyl-5- -propionic acid, 3-[(2-Phenyl- acid, 3- {[2-(4-Methyl-3-trifluoromethyl- phenyl)-benzo[b] thiophen-5 -ylmthyl] -amino) -propionic acid, 1 -[2-(3-Trifluoromethyl- pheny1)-benzo[b]thiophel-5-ylmethyl]-azetidile-3-caboxylic acid, 3- {[2-(4-Fluoro-3- tri fluoromethyl-pheny)-benzo[b] thiophel-5 -ylmthyl] aminlo) -propionic acid, 2-Fluoro-3- -tifluoromethy1-phenyI)-benzo[blthiophel-5 -ylmethyl l-amino) -propionic acid, -Bis-tri fluoromethy-phel)-beflzo[blthiophefl5 -ylmethyl -amino) -propionic acid, 3- ([2-(4-Tri fluoromethoxy-pheny1)-belzo~b] thiophel-5 -ylmethyl] -amino)} -propioni c acid, I- (2-(2-Fluoro-5-trifluoromethy-phel)-bezo[b]thiophe-5-y11Tethyl] -azetidine-3 carboxylic acid, 3- {[2-(2-Chloro-5-trifluoromethyl-phel)-beflzo[blthiophefl-5-yimethyIF- amino) -propionic acid, 3- {[2-(3-Trifluoromethy1-pheny1)-benzo[b]thiophel-5-ylmethy1I- amino) -propionic acid, 1 -[2-(3-TrifluoromethyI-pheny1)-benzo[b]thiophel-5-ylzmethyl]- pyrrolidine-3-carboxylic acid, 3- {[2-(2-Fluoro5-trifluoromethyl-phenyl)-beflzo[b]thiophen- -ylmethy1I -amino) -propionic acid, 3- {[2-(4-Trifluoromethyl-phenyl)-belzo[blthiophefl-5- ylmethyl] -amino} -propionic acid, 3- {[2-(4-Methoxy-3-trifluoroniethyl-phelyl)- -ylmethyl] -amino) -propionic acid, 3- {[2-(2-Methoxy-5-tri fluoromethyl- -amino) -propionic acid, 3- ([3-(2-Trifluoromethyl- -amino} -propionic acid, 3- Trifluoromethyl-bipheny-4-y)-be1zo~b] thiophefl2-yflmethyll amino)} -propionic acid, 3- 5 (-ylhxl3-r looehlpey)bnobtipe--lehl aio propionic acid, 3- {[3-Chloro-5-(2-trifluoromethy1-biphenl-4-yl)-beflzo[b]thiophefl2- C ylmethyl]-amnino} -propionic acid, 1 -[5-(2-Tri fluoromethyl-biphenyl-4-yl)-benzo[bthiophen- 2-ylmethyl]-azetidine-3-carboxylic acid, 3- {[3-Bromo-5-(2-trifluoromethyl-biphenyl-4-yl)- benzo[b]thiophen-2-ylmethyl]-amnino) -propionic acid, 3- {12-(2'-Fluoro-2-trifluoromethyl- -propionic acid, 3- {[2-(3'-Fluoro-2- trifluoromethyl-biphenyl-4-yl)-benzooxazol-5 -ylmethyl] -amino) -propionic acid, 3- Chloro-2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-5-ylmethyl] -amino) -propionic acid, 00 M 3 [2-(4-Phenoxy-3 -tri fluoromethyl-phenyl)-benzooxazol-5 -ylmethyl] -amino) -propionic acid, 3- {[2-(2'-Fluoro-2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylniethyl]-amino) N propionic acid, 3- {[2-(4-Cyclohexyl-3-trifluoromethyl-phenyl)-benzooxazol-6-ylmethyl]- amino) -propionic acid, 3- {12-(2-Trifluoromthyl-biphenyl-4-y)-benzooxazol-6-ylmethyl]- N amino) -propionic acid, 3- {[2-(5'-Fluoro-2'-methyl-2-trifluoromethyl-biphenyl-4-yl)- benzooxazol-6-ylmethyl]-amino} -propionic acid, 2-Fluoro-3 -{[2-(2'-fluoro-2- tri fluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- Dichloro-2-(2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- {[2-(3Y-Chloro-2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl]-amino)}- propionic acid, 3- {[5-Chloro-2-(2-trifluoromethyl-biphenyl-4-yI)-benzooxazol-6-ylmethyl]- amino) -propionic acid, 3- {[5-Bromo-2-(2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-6- ylmethyl] -amino) -propionic acid, 3- {[2-(4-Isobutyl-3-trifluoromethyl-phenyl)-benzooxazol- 6-ylmethyl] -amino) -propionic acid, 3- {[2-(4-Benzo[1I,3]dioxol-5-yl-3-trifluoromethyl- phenyl)-benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- {[2-(4-Cyclohexyl-3-fluoro- phenyl)-benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- {[2-(2-Fluoro-biphcnyl-4-yl)- benzooxazol-6-ylmethyl]-amnino) -propionic acid, 3- {[2-(3'-Chloro-4'-fluoro-2- trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- sec-Butyl-3 -trifluoromethyl-phenyl)-benzooxazol-6-ylmethyl] -amino) -propionic acid, Ethyl-2-(2-trifluoromethyl-biphenyl-4-yl)-benzooxazol-6-ylmethyl]-amino) -propionic acid, 3- [2-(4-Naphthalen-2-yl-3 -tri fluoromethyl-phenyl)-benzooxazol-6-ylmethyl] -amino) propionic acid, I- {2-[4-(2,2-Dimethyl-propyl)-3-trifluoromethyl-phenyl]-benzooxazol-6- ylmethyl) -azetidine-3-carboxylic acid, 3- {[2-(4-Butyl-3-trifluoromethyl-phenyl)- benzooxazol-6-ylmethyl] -amino) -propionic acid, 3- {[2-(4-Benzofuran-2-yl-3- trifluoromethyl-phenyl)-benzooxazol-6-ylmethyl] -amino) -propionic acid, Difluoro-benzyl)-3-trifluoromethyl-phenyl]-benzooxazol-6-yIrn'ethyl) -aniino)-propionic acid, 3 (-hnty3tr flooehlpey)bezoao--lehl -amino) N propionic acid, 3 tyryl-3 -trifluoromethy-pheny)-benzooxazoI-6-ylmethyl] -aminlo) propionic acid, (2-114-( 1 Pheny1-ethyl)-3-trifluoromethy-phel-bezooxazo1-6- ylmethyl) -amino)-propionic acid, 3- '-Fhioro-2'-methoxy-2-trifluoromethyl-bipheflyl- M 5 4-y1)-benzooxazo-6-ylmethy1]-methyI-amfilo}-propionic acid, 3- '-Fluoro-2'-methoxy- 00 looehlbpey--l-ezoao--lehl aio -propionic acid, 3- Trifluoromethyl-phenyl)-bezooxazol- 6 -ylmethyl] -amino) -propionic acid, [2-(4-tert- Buty1-phenyl)-b ezooxazo-6-ylmethyl] -amino)} -propionic acid, I -[2-(2-Fluoro-5- trifluoromethyl-phenyl)-bezooxazol-6-ylmethyl] -azetidine-3-carboxylic acid, 3- 2-(3 -tri fluoromethyl-pheny1)-bezooxazol-6-ylmethylI -amino) -propionic acid, I hnl-ezoxzl5ymty]aeiie3croyi acid, 1- [2(-loo5tilooehlpey)bnzfrn5ymty]aeiie3croyi acid, 3 {[2-(4-Chloro-3-trifluoromethy[-phefl)-belzooxazo16-ylmethyl] -amino) -propionic acid, 3- {[2-(4-Gyclopropy1-3-trifluoromethyl-phel)-benzoxazo16-ylmethyl] -amnino) -propionic acid, 3- {[2-(4-Fluoro-pheny1)-benzoxazol-6-ylmethyI]-amino) -propionic acid, 3- Fluoro-pheny1)-benzoxazoI-6-ylmethyI)-aifno) -propionic acid, 3- [2-(2-Fluoro-phenyl)- benzoox azol-6-ylmethyl] -aminlo) -propionic acid, 3- {[2-(4-Cyclohexyl-3-trifluoromethyl- phenyl)-benzo furan-5 -ylmethyl] -amino)} -propioni c acid, 3- {[2-(4-Cyclohexyl-3- trifluoromethyl-phenyl)-2,3-dihydro- I H-i soindol- 5-ylmethyl] -amino) -propionic acid, 3- [2- (4-Cyclohexy-3-tri fluoromethy1-phel)-2H-isoildo-5-yllnethyl] -amino) -propionic acid, 3- {[2-(2-Trifluoromethy-bipheny1-4-y1)-belzothiazoI-5-ylmethyI] -amino) -propionic acid, 3 [2-(2-Trifluoromethy-biphnyI-4-y1)-beflzothiazo1-7-ylmethyI] -amino) -propionic acid, 3- {[2-(3-Trifluoromethy-pheny)-benzothiazo-7-yflmethylI-amilo) -propionic acid, 3- (2-Tri fluoromethy-bipheny-4-y) -2H-ildazol-6-ylmethyll-aminlo) -propionic acid, 3- Fluoro-2-tifluoromethyl-biphefylY4y)2Hifdazol 6 ylmethyl] -amino) -propionic acid, I- [2(-loo2tilooehlbphn 4y)2-nao--lehl-azetidine-3- carboxylic acid, 1 -[2-(2-Tri fluoromethyl-biphenyl-4-yI)- IH-benzoimidazol-5-ylmethyll azetidine-3-carboxylic acid, 3- -Methyl-2-(2-trifluoromethyl-bipheflyl-4-yI)-3H- -amino) -propionic acid, 3- -Methyl-2-(2-trifluoromethyl- biphenyl-4-yI)- I H-benzoimidazol-5 -ylmethyl] -amino)I -propionic acid, 3- Trifluoromethyl-bipheflyl-4-ylmethyl)-2,3 -dihydro- I H-isoindol-5-ylmethyl] -amino) Spropionic acid, 3- {[2-(2-Trifluoromethyl-biphenyl-4-ylamino)-benzooxazol-5-ylmethyl]- C amino}-propionic acid, 3-({2-[Methyl-(2-trifluoromethyl-biphenyl-4-yl)-amino]- acid, 3-{[4-Oxo-2-(2-trifluoromethyl-biphenyl- S 4-yl)-4H-chromen-7-ylmethyl]-amino)-propionic acid, 3- [4-Oxo-2-(2-trifluoromethyl- biphenyl-4-yl)-4H-chromen-6-ylmethyl]-amino}-propionic acid and 1-[4-Oxo-2-(2- trifluoromethyl-biphenyl-4-yl)-4H-chromen-6-ylmethyl]-azetidine-3-carboxylic acid.
[9] 9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.
[10] A method for treating a disease in an animal in which alteration of EDG/S1P receptor mediated signal transduction can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1.
[11] 11. A method for preventing or treating disorders or diseases mediated by lymphocytes, for preventing or treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases, for inhibiting or controlling deregulated angiogenesis, or for preventing or treating diseases mediated by a neo-angiogenesis process or associated with deregulated angiogenesis in a subject comprising administering to the subject in need thereof an effective amount of a compound of claimsl, or a pharmaceutically acceptable salt thereof.
[12] 12. The use of a compound of claim 1 in the manufacture of a medicament for treating a disease in an animal in which alteration of EDG/S 1P receptor mediated signal transduction contributes to the pathology and/or symptomology of the disease.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2009200338B2|2011-11-17|Immunosuppressant compounds and compositions

---

AU2009200362B2|2011-12-01|Immunosuppressant compounds and compositions

---

US7462629B2|2008-12-09|Immunosuppressant compounds and compositions

---

EP1633336B1|2016-06-22|Immunosuppressant compounds and compositions

---

AU2005216540B2|2008-06-26|Immunosuppressant compounds and compositions

---

EP1917240A1|2008-05-07|Immunosuppressant compounds and compositions

---

AU2011224085B2|2013-03-07|Immunosuppressant compounds and compositions

---

AU2011224087B2|2013-03-07|Immunosuppressant compounds and compositions

同族专利:

---

公开号 | 公开日

---

AU2009200338B2|2011-11-17|

---

MXPA05012461A|2006-02-22|

---

US20090131400A1|2009-05-21|

---

EP1628967A1|2006-03-01|

---

HK1090639A1|2006-12-29|

---

JP4944613B2|2012-06-06|

---

US7750021B2|2010-07-06|

---

EP2644195A1|2013-10-02|

---

EP1628967A4|2011-04-27|

---

US7417065B2|2008-08-26|

---

CA2524048C|2013-06-25|

---

BRPI0410439A|2006-06-06|

---

US20050014725A1|2005-01-20|

---

EP1628967B1|2014-04-09|

---

JP2006528698A|2006-12-21|

---

TW200505442A|2005-02-16|

---

CA2524048A1|2005-01-06|

---

WO2005000833A1|2005-01-06|

---

CL2004001120A1|2005-04-15|

---

AR044402A1|2005-09-14|

---

PE20050158A1|2005-05-12|

---

ES2467160T3|2014-06-12|

---

AU2004251146A1|2005-01-06|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

FR901228A|1943-01-16|1945-07-20|Deutsche Edelstahlwerke Ag|Ring gap magnet system|

---

CH540247A|1967-04-21|1973-09-28|Ciba Geigy Ag|Process for the preparation of heterocyclic compounds containing asthylene double bonds|

---

US4526896A|1978-12-26|1985-07-02|Riker Laboratories, Inc.|Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof|

---

IL86632D0|1987-06-15|1988-11-30|Ciba Geigy Ag|Derivatives substituted at methyl-amino nitrogen|

---

NZ243082A|1991-06-28|1995-02-24|Ici Plc|4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof|

---

DE59208448D1|1991-08-15|1997-06-12|Ciba Geigy Ag|N-acyl-N-heterocyclyl or naphthylalkyl amino acids as angiotensin II antagonists|

---

GB9300059D0|1992-01-20|1993-03-03|Zeneca Ltd|Quinazoline derivatives|

---

TW225528B|1992-04-03|1994-06-21|Ciba Geigy Ag||

---

WO1994010202A1|1992-10-28|1994-05-11|Genentech, Inc.|Vascular endothelial cell growth factor antagonists|

---

GB9314893D0|1993-07-19|1993-09-01|Zeneca Ltd|Quinazoline derivatives|

---

US5362718A|1994-04-18|1994-11-08|American Home Products Corporation|Rapamycin hydroxyesters|

---

DE69522717T2|1995-03-30|2002-02-14|Pfizer|quinazoline derivatives|

---

GB9508538D0|1995-04-27|1995-06-14|Zeneca Ltd|Quinazoline derivatives|

---

US5880141A|1995-06-07|1999-03-09|Sugen, Inc.|Benzylidene-Z-indoline compounds for the treatment of disease|

---

SK398A3|1995-07-06|1998-07-08|Novartis Ag|Pyrrolopyrimidines and processes for the preparation thereof|

---

US5760041A|1996-02-05|1998-06-02|American Cyanamid Company|4-aminoquinazoline EGFR Inhibitors|

---

GB9603095D0|1996-02-14|1996-04-10|Zeneca Ltd|Quinazoline derivatives|

---

CN1145614C|1996-04-12|2004-04-14|沃尼尔·朗伯公司|Irreversible inhibitors of tyrosine kinases|

---

US5747498A|1996-05-28|1998-05-05|Pfizer Inc.|Alkynyl and azido-substituted 4-anilinoquinazolines|

---

EP0907642B1|1996-06-24|2005-11-02|Pfizer Inc.|Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases|

---

WO1998002441A2|1996-07-12|1998-01-22|Ariad Pharmaceuticals, Inc.|Non immunosuppressive antifungal rapalogs|

---

DE19638745C2|1996-09-11|2001-05-10|Schering Ag|Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein |

---

EP0954315A2|1996-09-13|1999-11-10|Sugen, Inc.|Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders|

---

EP0837063A1|1996-10-17|1998-04-22|Pfizer Inc.|4-Aminoquinazoline derivatives|

---

CO4950519A1|1997-02-13|2000-09-01|Novartis Ag|PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION|

---

CO4940418A1|1997-07-18|2000-07-24|Novartis Ag|MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE|

---

TW557297B|1997-09-26|2003-10-11|Abbott Lab|Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same|

---

GB9721069D0|1997-10-03|1997-12-03|Pharmacia & Upjohn Spa|Polymeric derivatives of camptothecin|

---

WO2000009495A1|1998-08-11|2000-02-24|Novartis Ag|Isoquinoline derivatives with angiogenesis inhibiting activity|

---

GB9824579D0|1998-11-10|1999-01-06|Novartis Ag|Organic compounds|

---

WO2000027819A2|1998-11-10|2000-05-18|Schering Aktiengesellschaft|Antrhranilic acid amides and the use thereof as medicaments|

---

AT300957T|1998-12-22|2005-08-15|Genentech Inc|ANTAGONISTS OF VASCULAR ENDOTHELIAL CELL GROWTH FACTORS AND ITS APPLICATION|

---

EP1165085B1|1999-03-30|2006-06-14|Novartis AG|Phthalazine derivatives for treating inflammatory diseases|

---

IL147803D0|1999-08-24|2002-08-14|Ariad Gene Therapeutics Inc|28-epirapalogs|

---

JP2001151771A|1999-09-10|2001-06-05|Kyowa Hakko Kogyo Co Ltd|Nitrogen-containing aromatic heterocyclic derivative|

---

EP1226136B1|1999-10-19|2004-12-29|Merck &amp; Co., Inc.|Tyrosine kinase inhibitors|

---

CA2387840A1|1999-10-19|2001-04-26|Scott R. Hambaugh|Tyrosine kinase inhibitors|

---

JP2004529100A|2001-01-30|2004-09-24|ユニバーシティオブバージニアパテントファウンデーション|Agonists and antagonists of sphingosine-1-phosphate receptor|

---

ES2316613T3|2001-05-10|2009-04-16|Ono Pharmaceutical Co., Ltd.|DERIVATIVES OF CRBOXILIC ACID AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT.|

---

US7030150B2|2001-05-11|2006-04-18|Trimeris, Inc.|Benzimidazole compounds and antiviral uses thereof|

---

AU2002323406A1|2001-08-30|2003-03-18|Merck And Co., Inc.|Tyrosine kinase inhibitors|

---

AU2003216054B2|2002-01-18|2007-01-04|Merck & Co., Inc.|Selective S1P1/Edg1 receptor agonists|

---

EP1470137B1|2002-01-18|2009-09-02|Merck & Co., Inc.|Edg receptor agonists|MY150088A|2003-05-19|2013-11-29|Irm Llc|Immunosuppressant compounds and compositions|

---

AU2004268455B2|2003-08-29|2009-12-17|Ono Pharmaceutical Co., Ltd.|Compound capable of binding S1P receptor and pharmaceutical use thereof|

---

TW200538433A|2004-02-24|2005-12-01|Irm Llc|Immunosuppressant compounds and compositiions|

---

MX2007001661A|2004-08-13|2007-04-23|Praecis Pharm Inc|Methods and compositions for modulating sphingosine-1-phosphatereceptor activity.|

---

EP2384749A1|2004-11-29|2011-11-09|Novartis AG|Dosage regimen of an S1P receptor agonist|

---

GB0500020D0|2005-01-04|2005-02-09|Novartis Ag|Organic compounds|

---

AU2006212866A1|2005-02-08|2006-08-17|Novartis Ag|Antilymphocyte antibody induction by combination of an S1P receptor agonist/modulator and of immunosuppressive drugs|

---

GB0504544D0|2005-03-04|2005-04-13|Novartis Ag|Organic compounds|

---

WO2006104668A2|2005-03-11|2006-10-05|Temple University - Of The Commonwealth System Of Higher Education|Composition and methods for the treatment of proliferative diseases|

---

JPWO2006115188A1|2005-04-22|2008-12-18|第一三共株式会社|Heterocyclic compounds|

---

US8334290B2|2005-10-31|2012-12-18|Merck Sharp & Dohme Corp.|CETP inhibitors|

---

AU2006317689B2|2005-11-23|2013-07-25|Epix Delaware, Inc.|S1P receptor modulating compounds and use thereof|

---

US7919519B2|2005-11-23|2011-04-05|Epix Pharmaceuticals Inc.|S1P receptor modulating compounds and use thereof|

---

MX2009010060A|2007-03-21|2010-01-20|Epix Pharm Inc|Sip receptor modulating compounds and use thereof.|

---

TW200806633A|2006-03-21|2008-02-01|Epix Pharm Inc|S1P receptor modulating compounds and use thereof|

---

US20090324581A1|2006-05-09|2009-12-31|Daiichi Sankyo Company Limited|Heteroarylamide lower carboxylic acid derivative|

---

WO2007129473A1|2006-05-09|2007-11-15|Daiichi Sankyo Company, Limited|Bicyclic aryl derivative|

---

GB0612721D0|2006-06-27|2006-08-09|Novartis Ag|Organic compounds|

---

JP2009269819A|2006-08-25|2009-11-19|Asahi Kasei Pharma Kk|Amine compound|

---

AT505454T|2007-09-20|2011-04-15|Amgen Inc|1--BENZYL) -AZETIDINE-3-CARBOXYLIC ACID DERIVATIVES AND CORRESPONDING COMPOUNDS AS S1P RECEPTOR MODULATORS FOR THE TREATMENT OF IMMUNE DISEASES|

---

SI2952177T1|2007-10-12|2021-07-30|Novartis Ag|Compositions comprising sphingosine 1 phosphatereceptor modulators|

---

GB0725101D0|2007-12-21|2008-01-30|Glaxo Group Ltd|Compounds|

---

GB0807910D0|2008-04-30|2008-06-04|Glaxo Group Ltd|Compounds|

---

TW201000099A|2008-06-20|2010-01-01|Amgen Inc|S1P1 receptor agonists and use thereof|

---

CN102159582B|2008-07-15|2014-05-07|赛诺菲-安万特|Oxazolopyrimidines as edg-1 receptor agonists|

---

AU2013209344B2|2008-07-23|2015-12-24|Novartis Ag|Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation|

---

WO2010010127A1|2008-07-23|2010-01-28|Novartis Ag|Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation|

---

CN102164891B|2008-07-23|2014-09-03|艾尼纳制药公司|Substituted 1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl) acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders|

---

AU2009288738B9|2008-08-27|2015-04-16|Arena Pharmaceuticals, Inc.|Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders|

---

EP2354134B1|2008-12-05|2016-02-24|Astellas Pharma Inc.|2h-chromene derivatives as stimulators of sphingosine 1-phosphate receptor|

---

AR074825A1|2008-12-22|2011-02-16|Novartis Ag|DOSAGE REGIME OF AN S1P RECEIVER AGONIST, TREATMENT METHOD AND KIT|

---

EP2382212B1|2009-01-23|2014-07-16|Bristol-Myers Squibb Company|Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases|

---

CN102361868A|2009-01-23|2012-02-22|百时美施贵宝公司|Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists|

---

WO2010085582A1|2009-01-23|2010-07-29|Bristol-Myers Squibb Company|Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases|

---

CN102548409B|2009-08-05|2015-11-25|比奥根Ma公司|Bicyclic aryl sphingosine 1-phosphate analogs|

---

US8399451B2|2009-08-07|2013-03-19|Bristol-Myers Squibb Company|Heterocyclic compounds|

---

MX336881B|2009-10-29|2016-02-04|Squibb Bristol Myers Co|Tricyclic heterocyclic compounds.|

---

AR079980A1|2010-01-13|2012-03-07|Sanofi Aventis|DERIVATIVES OF OXAZOLOPIRIMIDINE REPLACED BY 2,5,7|

---

TWI478929B|2010-01-13|2015-04-01|Sanofi Aventis|Carboxylic acid derivatives comprising a 2,5,7-substituted oxazolopyrimidine ring|

---

TWI517851B|2010-01-13|2016-01-21|賽諾菲阿凡提斯公司|Heterocyclic carboxylic acid derivatives comprising a 2,5,7-substituted oxazolopyrimidine ring|

---

CN102834399B|2010-01-14|2015-04-22|赛诺菲|Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring|

---

SG182484A1|2010-01-14|2012-08-30|Sanofi Sa|Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring|

---

TWI544926B|2010-01-14|2016-08-11|賽諾菲阿凡提斯公司|2,5-substituted oxazolopyrimidine derivatives|

---

SG182610A1|2010-01-27|2012-08-30|Arena Pharm Inc|Processes for the preparation of -2-benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof|

---

US8791100B2|2010-02-02|2014-07-29|Novartis Ag|Aryl benzylamine compounds|

---

SG10201501575VA|2010-03-03|2015-04-29|Arena Pharm Inc|Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof|

---

CN103119038B|2010-04-23|2016-05-04|百时美施贵宝公司|As 4- mandelic acidamide of S1P 1 receptor stimulating agent|

---

EP2595969B1|2010-07-20|2015-04-22|Bristol-Myers Squibb Company|Substituted 3-phenyl-1,2,4-oxadiazole compounds|

---

ES2548258T3|2010-09-24|2015-10-15|Bristol-Myers Squibb Company|Oxadiazole compounds substituted and their use as S1P1 agonists|

---

JP2013544811A|2010-11-03|2013-12-19|ブリストル−マイヤーズスクイブカンパニー|Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases|

---

JP5617799B2|2010-12-07|2014-11-05|信越化学工業株式会社|Chemically amplified resist material and pattern forming method|

---

CN106278999B|2011-02-07|2019-10-25|比奥根Ma公司|S1P regulator|

---

SG194184A1|2011-04-14|2013-11-29|Allergan Inc|Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators|

---

KR20140048875A|2011-04-18|2014-04-24|알러간, 인코포레이티드|Substituted bicyclic methyl amine derivatives as sphingosine-1-phosphate receptors modulators|

---

US8907093B2|2011-07-07|2014-12-09|Sanofi|Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring|

---

WO2013008095A1|2011-07-08|2013-01-17|Novartis Ag|Novel pyrrolo pyrimidine derivatives|

---

WO2013057212A1|2011-10-21|2013-04-25|Novartis Ag|Dosage regimen for an s1p receptor modulator or agonist|

---

EP2925721B1|2012-11-20|2017-06-07|Biogen MA Inc.|S1p and/or atx modulating agents|

---

US9771326B2|2012-11-20|2017-09-26|Biogen Ma Inc.|S1P and/or ATX modulating agents|

---

UY35338A|2013-02-21|2014-08-29|Bristol Myers Squibb Company Una Corporación Del Estado De Delaware|BICYCLIC COMPOUNDS MODULATING THE ACTIVITY OF S1P1 AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

US9512084B2|2013-11-29|2016-12-06|Novartis Ag|Amino pyrimidine derivatives|

---

JP6466461B2|2014-02-03|2019-02-06|ヴァイティー ファーマシューティカルズ，インコーポレイテッド|Dihydropyrrolopyridine inhibitors of ROR gamma|

---

KR101987107B1|2014-03-31|2019-06-10|동우 화인켐 주식회사|Colored photosensitive resin composition and color filter manufactured by the same|

---

MA40082B1|2014-08-20|2019-09-30|Squibb Bristol Myers Co|New Sphingosine Phosphate Substitution Compound Useful Treatment Disease Rheumatism|

---

UA118989C2|2014-10-14|2019-04-10|Вітае Фармасьютікалс, Інк.|Dihydropyrrolopyridine inhibitors of ror-gamma|

---

US9663515B2|2014-11-05|2017-05-30|Vitae Pharmaceuticals, Inc.|Dihydropyrrolopyridine inhibitors of ROR-gamma|

---

US9845308B2|2014-11-05|2017-12-19|Vitae Pharmaceuticals, Inc.|Isoindoline inhibitors of ROR-gamma|

---

MX2017008925A|2015-01-06|2017-10-11|Arena Pharm Inc|Methods of treating conditions related to the s1p1 receptor.|

---

KR101987108B1|2015-03-26|2019-06-10|동우 화인켐 주식회사|Colored photosensitive resin composition and color filter manufactured by the same|

---

KR20160115303A|2015-03-26|2016-10-06|동우 화인켐 주식회사|Colored photosensitive resin composition and color filter manufactured by the same|

---

KR102233483B1|2015-03-27|2021-03-26|동우 화인켐 주식회사|Colored photosensitive resin composition and color filter manufactured by the same|

---

KR20160115560A|2015-03-27|2016-10-06|동우 화인켐 주식회사|Colored photosensitive resin composition and color filter manufactured by the same|

---

KR20160116805A|2015-03-31|2016-10-10|동우 화인켐 주식회사|Colored photosensitive resin composition and color filter manufactured by the same|

---

MA42807A|2015-06-22|2018-07-25|Arena Pharm Inc|SALT L-ARGININE CRYSTALLINE ACID-2-BENZYLOXY) -1,2,3,4-TETRAHYDROCYCLO-PENTA [B] INDOL-3-YL) ACETICFOR USE IN CONDITIONS ASSOCIATED WITH THE S1P1 RECEIVER|

---

ES2856931T3|2015-08-05|2021-09-28|Vitae Pharmaceuticals Llc|ROR-gamma modulators|

---

AU2016355710B2|2015-11-20|2021-03-25|Vitae Pharmaceuticals, Llc|Modulators of ROR-gamma|

---

KR102335628B1|2015-12-28|2021-12-03|동우 화인켐 주식회사|Colored photosensitive resin composition, color filter and image display device produced using the same|

---

MX2018009257A|2016-01-29|2018-11-09|Vitae Pharmaceuticals Inc|Benzimidazole derivatives as modulators of ror-gamma.|

---

US9481674B1|2016-06-10|2016-11-01|Vitae Pharmaceuticals, Inc.|Dihydropyrrolopyridine inhibitors of ROR-gamma|

---

WO2018045149A1|2016-09-02|2018-03-08|Bristol-Myers Squibb Company|Substituted tricyclic heterocyclic compounds|

---

MX2019007416A|2016-12-22|2019-12-11|Incyte Corp|Benzooxazole derivatives as immunomodulators.|

---

BR112019012957A2|2016-12-22|2019-11-26|Incyte Corp|tetrahydroimidazo [4,5-c] pyridine derivatives as inducers of internalization of pd-11|

---

ES2874756T3|2016-12-22|2021-11-05|Incyte Corp|Triazolo [1,5-A] pyridine derivatives as immunomodulators|

---

US10913739B2|2017-07-24|2021-02-09|Vitae Pharmaceuticals, LLC |Inhibitors of RORγ|

---

WO2019018975A1|2017-07-24|2019-01-31|Vitae Pharmaceuticals, Inc.|Inhibitors of ror gamma|

---

US11059784B2|2017-08-09|2021-07-13|Bristol-Myers Squibb Company|Oxime ether compounds|

---

WO2019032632A1|2017-08-09|2019-02-14|Bristol-Myers Squibb Company|Alkylphenyl compounds|

---

CA3079959A1|2017-10-27|2018-10-26|Transfusion Health, Llc|Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene|

---

CN112135824A|2018-03-30|2020-12-25|因赛特公司|Heterocyclic compounds as immunomodulators|

---

JP2021524842A|2018-05-11|2021-09-16|インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ|Tetrahydro-imidazole [4,5-C] pyridine derivative as PD-L1 immunomodulator|

---

WO2020234779A1|2019-05-23|2020-11-26|Novartis Ag|Crystalline forms of a btk inhibitor|

法律状态:
2012-03-15| FGA| Letters patent sealed or granted (standard patent)|

---

2014-12-18| MK14| Patent ceased section 143(a) (annual fees not paid) or expired|

优先权:

---

申请号 | 申请日 | 专利标题

---

US47193103P| true| 2003-05-19|2003-05-19||

---

US60/471,931||2003-05-19||

---

US56218304P| true| 2004-04-14|2004-04-14||

---

US60/562,183||2004-04-14||

---

AU2004251146A|AU2004251146A1|2003-05-19|2004-05-19|Immunosuppressant compounds and compositions|

---

PCT/US2004/015702|WO2005000833A1|2003-05-19|2004-05-19|Immunosuppressant compounds and compositions|

---

AU2009200338A|AU2009200338B2|2003-05-19|2009-01-30|Immunosuppressant compounds and compositions|AU2009200338A| AU2009200338B2|2003-05-19|2009-01-30|Immunosuppressant compounds and compositions|